Human	human	JJ	O
leishmaniasis	leishmaniasis	NN	O
is	be	VBZ	O
caused	cause	VBN	O
by	by	IN	O
infection	infection	NN	O
with	with	IN	O
20	20	CD	O
protozoan	protozoan	NN	O
species	specie	NNS	O
belonging	belong	VBG	O
to	to	IN	O
the	the	DT	O
genus	genus	NNP	O
Leishmania	Leishmania	NNP	O
.	.	.	O

Between	between	IN	O
10	10	CD	O
and	and	CC	O
12	12	CD	O
million	million	CD	O
people	people	NNS	O
are	be	VBP	O
infected	infect	VBN	O
worldwide	worldwide	RB	O
,	,	,	O
with	with	IN	O
1â2	1â2	CD	O
new	new	JJ	O
million	million	CD	O
cases	case	NNS	O
per	per	IN	O
year	year	NN	O
,	,	,	O
and	and	CC	O
20,000â50,000	20,000â50,000	CD	O
deaths	death	NNS	O
per	per	IN	O
year	year	NN	B
.	.	.	O

Nowadays	nowadays	RB	O
,	,	,	O
leishmaniasis	leishmaniasis	NN	O
treatment	treatment	NN	O
is	be	VBZ	O
almost	almost	RB	O
exclusively	exclusively	RB	O
limited	limit	VBN	O
to	to	IN	O
chemotherapy	chemotherapy	VB	O
and	and	CC	O
confined	confine	VBN	O
to	to	IN	O
four	four	CD	O
main	main	JJ	O
drugs	drug	NNS	O
:	:	:	O
organic	organic	JJ	O
antimonials	antimonial	NNS	O
,	,	,	O
amphotericin	amphotericin	NN	O
B	B	NNP	O
,	,	,	O
miltefosine	miltefosine	NN	O
and	and	CC	O
paromomycin	paromomycin	NNS	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
current	current	JJ	O
effectiveness	effectiveness	NN	O
of	of	IN	O
the	the	DT	O
available	available	JJ	O
therapeutic	therapeutic	JJ	O
options	option	NNS	O
is	be	VBZ	O
increasingly	increasingly	RB	O
eroded	erode	VBN	O
by	by	IN	O
rising	rise	VBG	O
resistance	resistance	NN	O
,	,	,	O
implementation	implementation	NN	O
costs	cost	NNS	O
in	in	IN	O
low	low	JJ	O
income	income	NN	O
endemic	endemic	JJ	O
countries	country	NNS	O
,	,	,	O
and	and	CC	O
lack	lack	NN	O
of	of	IN	O
treatment	treatment	NN	O
compliance	compliance	NN	B
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
new	new	JJ	O
drugs	drug	NNS	O
under	under	IN	O
clinical	clinical	JJ	O
assays	assay	NNS	O
is	be	VBZ	O
rather	rather	RB	O
scarce	scarce	JJ	O
,	,	,	O
and	and	CC	O
new	new	JJ	O
alternatives	alternative	NNS	O
in	in	IN	O
terms	term	NNS	O
of	of	IN	O
drugs	drug	NNS	O
and	and	CC	O
validated	validated	JJ	O
targets	target	NNS	O
are	be	VBP	O
needed	need	VBN	O
to	to	TO	O
avert	avert	VB	O
this	this	DT	O
gloomy	gloomy	JJ	O
landscape	landscape	NN	B
.	.	.	O

Remarkably	remarkably	RB	O
,	,	,	O
modulation	modulation	NN	O
of	of	IN	O
protein	protein	NN	O
kinase	kinase	NN	O
activity	activity	NN	O
is	be	VBZ	O
an	an	DT	O
appealing	appeal	VBG	O
pharmacological	pharmacological	JJ	O
approach	approach	NN	O
to	to	TO	O
be	be	VB	O
exploited	exploit	VBN	O
as	as	IN	O
a	a	DT	O
drug	drug	NN	O
target	target	NN	O
,	,	,	O
as	as	IN	O
PKs	pk	NNS	O
regulate	regulate	VBP	O
a	a	DT	O
variety	variety	NN	O
of	of	IN	O
essential	essential	JJ	O
processes	process	NNS	O
in	in	IN	O
every	every	DT	O
living	live	VBG	O
organism	organism	NN	O
.	.	.	O

Nowadays	nowadays	RB	O
,	,	,	O
the	the	DT	O
druggable	druggable	JJ	O
kinome	kinome	NN	O
is	be	VBZ	O
the	the	DT	O
largest	large	JJS	O
group	group	NN	O
in	in	IN	O
pharmacology	pharmacology	NN	B
.	.	.	O

Thirty	thirty	CD	O
-	-	HYPH	O
seven	seven	CD	O
human	human	JJ	O
protein	protein	NN	O
kinase	kinase	NN	O
inhibitors	inhibitor	NNS	O
have	have	VBP	O
been	be	VBN	O
approved	approve	VBN	O
for	for	IN	O
clinical	clinical	JJ	O
use	use	NN	O
and	and	CC	O
more	more	JJR	O
than	than	IN	O
two	two	CD	O
hundred	hundred	CD	O
additional	additional	JJ	O
PKis	PKis	NNP	O
are	be	VBP	O
under	under	IN	O
clinical	clinical	JJ	O
trial	trial	NN	B
.	.	.	O

The	the	DT	O
aim	aim	NN	O
of	of	IN	O
these	these	DT	O
PKis	PKis	NNP	O
is	be	VBZ	O
to	to	TO	O
correct	correct	VB	O
aberrant	aberrant	JJ	O
protein	protein	NN	O
phosphorylation	phosphorylation	NN	O
syndromes	syndrome	VBZ	O
underlying	underlie	VBG	O
human	human	JJ	O
pathologies	pathology	NNS	O
such	such	JJ	O
as	as	IN	O
,	,	,	O
but	but	CC	O
not	not	RB	O
limited	limit	VBN	O
to	to	IN	O
,	,	,	O
cancer	cancer	NN	O
or	or	CC	O
neurodegenerative	neurodegenerative	JJ	O
diseases	disease	NNS	B
,	,	,	B
.	.	.	O

The	the	DT	O
characterisation	characterisation	NN	O
of	of	IN	O
the	the	DT	O
divergences	divergence	NNS	O
between	between	IN	O
the	the	DT	O
kinome	kinome	NN	O
of	of	IN	O
several	several	JJ	O
parasites	parasite	NNS	O
from	from	IN	O
those	those	DT	O
of	of	IN	O
their	-PRON-	PRP$	O
mammalian	mammalian	JJ	O
host	host	NN	O
has	have	VBZ	O
become	become	VBN	O
a	a	DT	O
source	source	NN	O
of	of	IN	O
new	new	JJ	O
targets	target	NNS	O
for	for	IN	O
novel	novel	JJ	O
anti	anti	JJ	O
-	-	JJ	O
infective	infective	JJ	O
drugs	drug	NNS	B
,	,	,	B
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
pharmacological	pharmacological	JJ	O
role	role	NN	O
of	of	IN	O
PKis	PKis	NNP	O
has	have	VBZ	O
been	be	VBN	O
extended	extend	VBN	O
beyond	beyond	IN	O
the	the	DT	O
selective	selective	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
PKs	PKs	NNP	O
from	from	IN	O
the	the	DT	O
pathogen	pathogen	NN	O
to	to	TO	O
revert	revert	VB	O
changes	change	NNS	O
in	in	IN	O
the	the	DT	O
protein	protein	NN	O
phosphorylation	phosphorylation	NN	O
pattern	pattern	NN	O
of	of	IN	O
the	the	DT	O
host	host	NN	O
,	,	,	O
driven	drive	VBN	O
by	by	IN	O
the	the	DT	O
pathogen	pathogen	NN	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
ensure	ensure	VB	O
its	-PRON-	PRP$	O
survival	survival	NN	O
inside	inside	IN	O
the	the	DT	O
host	host	NN	B
,	,	,	B
.	.	.	O

Concerning	concern	VBG	O
the	the	DT	O
former	former	JJ	O
mode	mode	NN	O
of	of	IN	O
action	action	NN	O
,	,	,	O
two	two	CD	O
different	different	JJ	O
approaches	approach	NNS	O
have	have	VBP	O
been	be	VBN	O
used	use	VBN	O
:	:	:	O
first	first	RB	O
,	,	,	O
the	the	DT	O
design	design	NN	O
of	of	IN	O
PKis	PKis	NNP	O
for	for	IN	O
atypical	atypical	JJ	O
kinases	kinase	NNS	O
of	of	IN	O
the	the	DT	O
pathogen	pathogen	NN	B
which	which	WDT	O
are	be	VBP	O
absent	absent	JJ	O
in	in	IN	O
the	the	DT	O
host	host	NN	O
,	,	,	O
and	and	CC	O
second	second	RB	O
,	,	,	O
to	to	TO	O
exploit	exploit	VB	O
the	the	DT	O
often	often	RB	O
subtle	subtle	JJ	O
differences	difference	NNS	O
between	between	IN	O
homologue	homologue	NNP	O
kinases	kinase	NNS	O
of	of	IN	O
the	the	DT	O
parasite	parasite	NN	O
and	and	CC	O
of	of	IN	O
the	the	DT	O
host	host	NN	B
.	.	.	O

The	the	DT	O
Leishmania	Leishmania	NNP	O
major	major	JJ	O
genome	genome	NN	O
contains	contain	VBZ	O
199	199	CD	O
PKs	pk	NNS	B
,	,	,	O
exclusively	exclusively	RB	O
belonging	belong	VBG	O
to	to	IN	O
the	the	DT	O
Ser	Ser	NNP	O
/	/	SYM	O
Thr	Thr	NNP	O
kinases	kinase	NNS	O
,	,	,	O
except	except	IN	O
for	for	IN	O
some	some	DT	O
kinases	kinase	NNS	O
with	with	IN	O
dual	dual	JJ	O
activity	activity	NN	O
as	as	IN	O
Ser	Ser	NNP	O
/	/	SYM	O
Thr	Thr	NNP	O
or	or	CC	O
Tyr	Tyr	NNP	O
kinases	kinase	NNS	O
.	.	.	O

Protein	protein	NN	O
kinases	kinase	NNS	O
are	be	VBP	O
involved	involve	VBN	O
in	in	IN	O
processes	process	NNS	O
such	such	JJ	O
as	as	IN	O
the	the	DT	O
inter	inter	JJ	O
-	-	JJ	O
stage	stage	JJ	O
differentiation	differentiation	NN	O
during	during	IN	O
the	the	DT	O
life	life	NN	O
cycle	cycle	NN	O
of	of	IN	O
the	the	DT	O
parasite	parasite	NN	B
,	,	,	O
macrophage	macrophage	NN	O
invasion	invasion	NN	B
,	,	,	O
response	response	NN	O
to	to	IN	O
stress	stress	VB	B
,	,	,	O
intracellular	intracellular	JJ	O
survival	survival	NN	O
in	in	IN	O
the	the	DT	O
host	host	NN	B
,	,	,	B
,	,	,	O
or	or	CC	O
drug	drug	NN	O
resistance	resistance	NN	B
,	,	,	O
among	among	IN	O
others	other	NNS	O
.	.	.	O

Several	several	JJ	O
groups	group	NNS	O
have	have	VBP	O
provided	provide	VBN	O
a	a	DT	O
consistent	consistent	JJ	O
proof	proof	NN	O
of	of	IN	O
concept	concept	NN	O
on	on	IN	O
the	the	DT	O
druggability	druggability	NN	O
of	of	IN	O
Leishmania	Leishmania	NNP	O
kinome	kinome	JJ	O
as	as	IN	O
a	a	DT	O
new	new	JJ	O
chemotherapy	chemotherapy	NN	O
venue	venue	NN	B
,	,	,	B
.	.	.	O

In	in	IN	O
fact	fact	NN	O
,	,	,	O
protein	protein	NN	O
phosphorylation	phosphorylation	NN	O
site	site	NN	O
descriptors	descriptor	NNS	O
for	for	IN	O
Leishmania	Leishmania	NNP	O
proteins	protein	NNS	O
have	have	VBP	O
been	be	VBN	O
reported	report	VBN	B
,	,	,	O
and	and	CC	O
PK	PK	NNP	O
inhibition	inhibition	NN	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
for	for	IN	O
a	a	DT	O
number	number	NN	O
of	of	IN	O
enzymes	enzyme	NNS	O
,	,	,	O
such	such	JJ	O
as	as	IN	O
Akt	Akt	NNP	O
-	-	HYPH	O
like	like	JJ	B
,	,	,	O
CK1.2	CK1.2	NNP	B
,	,	,	O
PKA	PKA	NNP	B
,	,	,	O
PKC	pkc	JJ	B
,	,	,	B
,	,	,	O
Aurora	Aurora	NNP	O
kinase	kinase	VBD	B
,	,	,	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
GSK-3	GSK-3	NNP	B
.	.	.	O

In	in	IN	O
mammalian	mammalian	JJ	O
cells	cell	NNS	O
,	,	,	O
glycogen	glycogen	NNP	O
synthase	synthase	NNP	O
kinase-3	kinase-3	NNP	O
is	be	VBZ	O
a	a	DT	O
multitask	multitask	NN	O
Ser	Ser	NNP	O
/	/	SYM	O
Thr	Thr	NNP	O
kinase	kinase	VBD	O
with	with	IN	O
functionalities	functionality	NNS	O
far	far	RB	O
beyond	beyond	IN	O
its	-PRON-	PRP$	O
inceptive	inceptive	JJ	O
regulation	regulation	NN	O
of	of	IN	O
the	the	DT	O
last	last	JJ	O
step	step	NN	O
in	in	IN	O
glycogen	glycogen	NNP	O
biosynthesis	biosynthesis	NN	O
.	.	.	O

GSK-3	GSK-3	NNP	O
is	be	VBZ	O
involved	involve	VBN	O
in	in	IN	O
a	a	DT	O
number	number	NN	O
of	of	IN	O
signalling	signal	VBG	O
pathways	pathway	NNS	O
implicated	implicate	VBN	O
in	in	IN	O
the	the	DT	O
regulation	regulation	NN	O
of	of	IN	O
processes	process	NNS	O
such	such	JJ	O
as	as	IN	O
receptor	receptor	NN	O
signalling	signalling	NN	O
,	,	,	O
cell	cell	NN	O
proliferation	proliferation	NN	O
,	,	,	O
cell	cell	NN	O
differentiation	differentiation	NN	O
and	and	CC	O
death	death	NN	O
,	,	,	O
embryonic	embryonic	JJ	O
development	development	NN	O
,	,	,	O
glycogen	glycogen	NN	O
and	and	CC	O
energy	energy	NN	O
metabolism	metabolism	NN	B
,	,	,	O
all	all	DT	O
accounting	account	VBG	O
for	for	IN	O
its	-PRON-	PRP$	O
druggability	druggability	NN	O
in	in	IN	O
human	human	JJ	O
pathologies	pathology	NNS	O
.	.	.	O

Counterparts	counterpart	NNS	O
of	of	IN	O
human	human	JJ	O
GSK-3	GSK-3	NNP	O
have	have	VBP	O
been	be	VBN	O
described	describe	VBN	O
in	in	IN	O
Leishmania	Leishmania	NNP	O
spp	spp	NN	O
.	.	.	O

Â	â	IN	O
and	and	CC	O
Trypanosoma	Trypanosoma	NNP	O
brucei	brucei	NN	O
.	.	.	O

Both	both	DT	O
organisms	organism	NNS	O
express	express	VBP	O
short-	short-	NNS	O
and	and	CC	O
long	long	JJ	O
-	-	HYPH	O
forms	form	NNS	O
of	of	IN	O
the	the	DT	O
enzyme	enzyme	NNS	O
,	,	,	O
each	each	DT	O
of	of	IN	O
them	-PRON-	PRP	O
encoded	encode	VBN	O
by	by	IN	O
different	different	JJ	O
genes	gene	NNS	O
.	.	.	O

Inhibition	inhibition	NN	O
of	of	IN	O
GSK-3	GSK-3	NNP	O
expression	expression	NN	O
by	by	IN	O
RNAi	RNAi	NNS	O
in	in	IN	O
the	the	DT	O
bloodstream	bloodstream	NN	O
form	form	NN	O
of	of	IN	O
Trypanosoma	Trypanosoma	NNP	O
brucei	brucei	NN	O
evidenced	evidence	VBD	O
the	the	DT	O
greater	great	JJR	O
importance	importance	NN	O
of	of	IN	O
short	short	JJ	O
GSK-3	GSK-3	NNP	O
over	over	IN	O
its	-PRON-	PRP$	O
long	long	JJ	O
isoform	isoform	NN	O
for	for	IN	O
parasite	parasite	NN	O
viability	viability	NN	B
.	.	.	O

Both	both	DT	O
forms	form	NNS	O
have	have	VBP	O
the	the	DT	O
same	same	JJ	O
active	active	JJ	O
site	site	NN	O
,	,	,	O
hence	hence	RB	O
it	-PRON-	PRP	O
can	can	MD	O
be	be	VB	O
surmised	surmise	VBN	O
that	that	IN	O
their	-PRON-	PRP$	O
pharmacological	pharmacological	JJ	O
inhibition	inhibition	NN	O
is	be	VBZ	O
likely	likely	JJ	O
to	to	TO	O
be	be	VB	O
similar	similar	JJ	B
.	.	.	O

There	there	EX	O
is	be	VBZ	O
a	a	DT	O
41	41	CD	O
%	%	NN	O
identity	identity	NN	O
in	in	IN	O
amino	amino	JJ	O
acids	acid	NNS	O
between	between	IN	O
the	the	DT	O
short	short	JJ	O
form	form	NN	O
of	of	IN	O
Leishmania	Leishmania	NNP	O
major	major	JJ	O
GSK-3	GSK-3	NNP	O
and	and	CC	O
the	the	DT	O
GSK-3Î²	gsk-3î²	NN	O
in	in	IN	O
humans	human	NNS	B
.	.	.	O

Nevertheless	nevertheless	RB	O
,	,	,	O
these	these	DT	O
differences	difference	NNS	O
are	be	VBP	O
reduced	reduce	VBN	O
to	to	IN	O
just	just	RB	O
3	3	CD	O
of	of	IN	O
the	the	DT	O
21	21	CD	O
amino	amino	NN	O
acid	acid	NN	O
sequence	sequence	NN	O
lining	line	VBG	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
.	.	.	O

Leishmania	Leishmania	NNP	O
donovani	donovani	NN	O
GSK-3	GSK-3	NNP	O
was	be	VBD	O
inhibited	inhibit	VBN	O
by	by	IN	O
6-bromo-5-methylindirubin-3'-oxime	6-bromo-5-methylindirubin-3'-oxime	RB	O
causing	cause	VBG	O
cell	cell	NN	O
cycle	cycle	NN	O
deregulation	deregulation	NN	O
and	and	CC	O
induction	induction	NN	O
of	of	IN	O
the	the	DT	O
apoptosis	apoptosis	NN	O
.	.	.	O

These	these	DT	O
lethal	lethal	JJ	O
effects	effect	NNS	O
were	be	VBD	O
partially	partially	RB	O
rescued	rescue	VBN	O
by	by	IN	O
overexpression	overexpression	NN	O
of	of	IN	O
the	the	DT	O
short	short	JJ	O
form	form	NN	O
of	of	IN	O
LdGSK-3	LdGSK-3	NNP	O
,	,	,	O
hence	hence	RB	O
the	the	DT	O
enzyme	enzyme	NNS	O
was	be	VBD	O
genetically	genetically	RB	O
and	and	CC	O
pharmacologically	pharmacologically	RB	O
validated	validate	VBN	B
.	.	.	O

The	the	DT	O
sequence	sequence	NN	O
of	of	IN	O
the	the	DT	O
short	short	JJ	O
form	form	NN	O
of	of	IN	O
GSK-3	GSK-3	NNP	O
was	be	VBD	O
preserved	preserve	VBN	O
in	in	IN	O
L.	L.	NNP	O
donovani	donovani	NNP	O
,	,	,	O
L.	L.	NNP	O
infantum	infantum	NN	O
,	,	,	O
and	and	CC	O
L.	L.	NNP	O
major	major	JJ	B
,	,	,	O
thus	thus	RB	O
,	,	,	O
inhibitors	inhibitor	NNS	O
against	against	IN	O
one	one	CD	O
form	form	NN	O
of	of	IN	O
the	the	DT	O
disease	disease	NN	O
,	,	,	O
either	either	CC	O
visceral	visceral	JJ	O
or	or	CC	O
cutaneous	cutaneous	JJ	O
,	,	,	O
will	will	MD	O
presumably	presumably	RB	O
be	be	VB	O
active	active	JJ	O
on	on	IN	O
the	the	DT	O
other	other	JJ	O
forms	form	NNS	O
,	,	,	O
enticing	entice	VBG	O
their	-PRON-	PRP$	O
potentiality	potentiality	NN	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
effects	effect	NNS	O
of	of	IN	O
human	human	JJ	O
GSK-3Î²	GSK-3Î²	NNP	O
inhibitors	inhibitor	NNS	O
may	may	MD	O
reduce	reduce	VB	O
the	the	DT	O
inflammatory	inflammatory	JJ	O
pathology	pathology	NN	O
associated	associate	VBN	O
with	with	IN	O
leishmaniasis	leishmaniasis	NN	B
.	.	.	O

These	these	DT	O
facts	fact	NNS	O
prompted	prompt	VBD	O
us	-PRON-	PRP	O
to	to	TO	O
search	search	VB	O
for	for	IN	O
novel	novel	JJ	O
leishmanicidal	leishmanicidal	NN	O
scaffolds	scaffold	NNS	O
where	where	WRB	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
Leishmania	Leishmania	NNP	O
GSK-3	GSK-3	NNP	O
played	play	VBD	O
a	a	DT	O
crucial	crucial	JJ	O
role	role	NN	O
.	.	.	O

For	for	IN	O
this	this	DT	O
purpose	purpose	NN	O
,	,	,	O
a	a	DT	O
dual	dual	JJ	O
yet	yet	CC	O
complementary	complementary	JJ	O
approach	approach	NN	O
was	be	VBD	O
taken	take	VBN	O
to	to	TO	O
enlarge	enlarge	VB	O
the	the	DT	O
chemical	chemical	NN	O
space	space	NN	O
explored	explore	VBN	O
.	.	.	O

First	first	RB	O
,	,	,	O
we	-PRON-	PRP	O
evaluated	evaluate	VBD	O
a	a	DT	O
small	small	JJ	O
set	set	NN	O
of	of	IN	O
hGSK-3Î²	hgsk-3î²	CD	O
inhibitors	inhibitor	NNS	O
previously	previously	RB	O
developed	develop	VBN	O
in	in	IN	O
our	-PRON-	PRP$	O
group	group	NN	O
,	,	,	O
chemically	chemically	RB	O
diverse	diverse	JJ	O
and	and	CC	O
with	with	IN	O
different	different	JJ	O
binding	binding	NN	O
modes	mode	NNS	O
to	to	IN	O
the	the	DT	O
human	human	JJ	O
enzyme	enzyme	NNS	O
.	.	.	O

These	these	DT	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
assayed	assay	VBN	O
as	as	IN	O
leishmanicidal	leishmanicidal	JJ	O
agents	agent	NNS	O
and	and	CC	O
complemented	complement	VBD	O
with	with	IN	O
the	the	DT	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
assessment	assessment	NN	O
of	of	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
short	short	JJ	O
LdGSK-3	LdGSK-3	NNP	O
.	.	.	O

Next	next	RB	O
,	,	,	O
we	-PRON-	PRP	O
explored	explore	VBD	O
186	186	CD	O
compounds	compound	NNS	O
from	from	IN	O
the	the	DT	O
Leishbox	Leishbox	NNP	O
collection	collection	NN	O
as	as	IN	O
LdGSK-3	LdGSK-3	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Leishbox	leishbox	NN	O
belongs	belong	VBZ	O
to	to	IN	O
TCAKS	TCAKS	NNP	O
,	,	,	O
an	an	DT	O
open	open	JJ	O
access	access	NN	O
collection	collection	NN	O
of	of	IN	O
compounds	compound	NNS	O
selected	select	VBN	O
through	through	IN	O
the	the	DT	O
screening	screening	NN	O
of	of	IN	O
1.8	1.8	CD	O
million	million	CD	O
molecules	molecule	NNS	O
from	from	IN	O
the	the	DT	O
GlaxoSmithKline	glaxosmithkline	NN	O
chemical	chemical	NN	O
library	library	NN	O
for	for	IN	O
leishmanicidal	leishmanicidal	JJ	O
and	and	CC	O
trypanocidal	trypanocidal	JJ	O
activity	activity	NN	O
particularly	particularly	RB	O
enriched	enrich	VBD	O
with	with	IN	O
chemotypes	chemotype	NNS	O
described	describe	VBN	O
as	as	IN	O
putative	putative	JJ	O
protein	protein	NN	O
kinase	kinase	VBD	O
inhibitors	inhibitor	NNS	O
,	,	,	O
according	accord	VBG	O
to	to	IN	O
a	a	DT	O
bioinformatic	bioinformatic	JJ	O
analysis	analysis	NN	B
.	.	.	O

Compounds	compound	NNS	O
in	in	IN	O
Leishbox	Leishbox	NNP	O
are	be	VBP	O
active	active	JJ	O
against	against	IN	O
axenic	axenic	JJ	O
and	and	CC	O
intracellular	intracellular	JJ	O
L.	L.	NNP	O
donovani	donovani	NN	O
amastigotes	amastigote	NNS	O
IC50	IC50	NNP	O
â¤5âÂµM	â¤5âÂµM	NNP	O
,	,	,	O
and	and	CC	O
devoid	devoid	JJ	O
of	of	IN	O
cytotoxicity	cytotoxicity	NN	O
on	on	IN	O
HepG2	HepG2	NNP	O
and	and	CC	O
THP-1	THP-1	NNP	O
cells	cell	NNS	O
.	.	.	O

On	on	IN	O
the	the	DT	O
whole	whole	NN	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
uncovered	uncover	VBN	O
11	11	CD	O
new	new	JJ	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
GSK-3	GSK-3	NNP	O
with	with	IN	O
leishmanicidal	leishmanicidal	JJ	O
activity	activity	NN	O
belonging	belong	VBG	O
to	to	IN	O
6	6	CD	O
different	different	JJ	O
chemical	chemical	NN	O
classes	class	NNS	O
,	,	,	O
with	with	IN	O
activities	activity	NNS	O
at	at	IN	O
the	the	DT	O
low	low	JJ	O
micromolar	micromolar	JJ	O
range	range	NN	O
.	.	.	O

The	the	DT	O
molecular	molecular	JJ	O
basis	basis	NN	O
of	of	IN	O
their	-PRON-	PRP$	O
inhibition	inhibition	NN	O
was	be	VBD	O
predicted	predict	VBN	O
by	by	IN	O
molecular	molecular	JJ	O
docking	docking	NN	O
studies	study	NNS	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
new	new	JJ	O
chemical	chemical	NN	O
scaffolds	scaffold	NNS	O
have	have	VBP	O
been	be	VBN	O
added	add	VBN	O
to	to	IN	O
the	the	DT	O
list	list	NN	O
of	of	IN	O
active	active	JJ	O
leishmanicidal	leishmanicidal	JJ	O
compounds	compound	NNS	O
with	with	IN	O
GSK-3	GSK-3	NNP	O
inhibitory	inhibitory	NN	O
properties	property	NNS	O
to	to	TO	O
be	be	VB	O
further	further	RB	O
optimised	optimise	VBN	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
commercial	commercial	JJ	O
reagents	reagent	NNS	O
were	be	VBD	O
of	of	IN	O
the	the	DT	O
highest	high	JJS	O
quality	quality	NN	O
available	available	JJ	O
.	.	.	O

Unless	unless	IN	O
otherwise	otherwise	RB	O
stated	state	VBN	O
,	,	,	O
they	-PRON-	PRP	O
were	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
SIGMA	SIGMA	NNP	O
-	-	HYPH	O
Aldrich	Aldrich	NNP	O
Spain	Spain	NNP	O
.	.	.	O

RPMI	RPMI	NNP	O
1640	1640	CD	O
medium	medium	NN	O
,	,	,	O
RPMI	RPMI	NNP	O
1640	1640	CD	O
without	without	IN	O
red	red	JJ	O
phenol	phenol	NN	O
,	,	,	O
and	and	CC	O
M199	M199	NNP	O
medium	medium	NN	O
,	,	,	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
Gibco	Gibco	NNP	O
.	.	.	O

Human	human	JJ	O
kinase	kinase	NN	O
inhibitors	inhibitor	NNS	O
tested	test	VBN	O
in	in	IN	O
this	this	DT	O
work	work	NN	O
were	be	VBD	O
previously	previously	RB	O
described	describe	VBN	B
and	and	CC	O
are	be	VBP	O
collected	collect	VBN	O
in	in	IN	O
the	the	DT	O
MBC	MBC	NNP	O
chemical	chemical	NN	O
library	library	NN	B
.	.	.	O

Their	-PRON-	PRP$	O
purity	purity	NN	O
was	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
elemental	elemental	JJ	O
analysis	analysis	NN	O
and	and	CC	O
values	value	NNS	O
were	be	VBD	O
within	within	IN	O
Â±0.4	â±0.4	ADD	O
%	%	NN	O
of	of	IN	O
the	the	DT	O
theoretical	theoretical	JJ	O
values	value	NNS	O
.	.	.	O

Leishbox	leishbox	NN	O
compounds	compound	VBZ	B
were	be	VBD	O
kindly	kindly	RB	O
provided	provide	VBN	O
by	by	IN	O
GlaxoSmithKline	glaxosmithkline	NN	O
as	as	IN	O
10âÂµL	10ââµl	CD	O
of	of	IN	O
10âmM	10âmm	CD	O
solution	solution	NN	O
in	in	IN	O
DMSO	DMSO	NNP	O
.	.	.	O

Leishmania	Leishmania	NNP	O
donovani	donovani	NN	O
promastigotes	promastigote	NNS	O
were	be	VBD	O
grown	grow	VBN	O
at	at	IN	O
26âÂ	26ââ	CD	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
RPMI	RPMI	NNP	O
1640	1640	CD	O
medium	medium	NN	O
supplemented	supplement	VBN	O
with	with	IN	O
5âmM	5âmm	CD	O
HEPES	HEPES	NNP	O
,	,	,	O
1.7âmM	1.7âmm	CD	O
HCO3Na	hco3na	NN	O
,	,	,	O
10	10	CD	O
%	%	NN	O
HIFCS	hifc	NNS	O
,	,	,	O
2âmM	2âmm	CD	O
L	l	NN	O
-	-	HYPH	O
glutamine	glutamine	NN	O
,	,	,	O
20âU	20âU	NNP	O
/	/	SYM	O
mL	mL	NNP	O
unicillin	unicillin	NNP	O
,	,	,	O
24âÂµg	24ââµg	CD	O
/	/	SYM	O
mL	mL	NNP	O
gentamicin	gentamicin	NNS	O
;	;	:	O
pH	pH	NNP	O
6.8â6.9	6.8â6.9	CD	O
.	.	.	O

L.	L.	NNP	O
pifanoi	pifanoi	NN	O
axenic	axenic	JJ	O
amastigotes	amastigote	NNS	O
were	be	VBD	O
grown	grow	VBN	O
at	at	IN	O
32âÂ	32ââ	CD	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
M199	M199	NNP	O
medium	medium	NN	O
supplemented	supplement	VBD	O
with	with	IN	O
20	20	CD	O
%	%	NN	O
HIFCS	hifc	NNS	O
,	,	,	O
0.5	0.5	CD	O
%	%	NN	O
trypticase	trypticase	NN	O
peptone	peptone	NN	O
,	,	,	O
13.9âmM	13.9âmm	CD	O
D	d	NN	O
-	-	HYPH	O
glucose	glucose	NN	O
,	,	,	O
76.7âÂµM	76.7ââµm	CD	O
haemin	haemin	NN	O
,	,	,	O
5.1âmM	5.1âmm	CD	O
glutamine	glutamine	NN	O
,	,	,	O
40âÂµg	40ââµg	CD	O
/	/	SYM	O
mL	mL	NNP	O
gentamicin	gentamicin	NNS	O
;	;	:	O
pH	pH	NNP	O
7â7.2	7â7.2	ADD	O
.	.	.	O

Kinase	Kinase	NNP	O
PBS	PBS	NNP	O
150âmM	150âmm	CD	O
NaCl	NaCl	NNP	O
,	,	,	O
1.5âmM	1.5âmm	CD	O
H2KPO4	h2kpo4	NN	O
,	,	,	O
2.7âmM	2.7âmm	CD	O
KCl	KCl	NNS	O
,	,	,	O
8.3âmM	8.3âmm	CD	O
HNa2PO4	hna2po4	NN	O
,	,	,	O
60âmM	60âmm	CD	O
Î²-glycerophosphate	î²-glycerophosphate	JJ	O
disodium	disodium	NN	O
salt	salt	NN	O
,	,	,	O
1âmM	1âmm	CD	O
Na3VO4	Na3VO4	NNP	O
,	,	,	O
1âmM	1âmm	CD	O
NaF	naf	NN	O
,	,	,	O
1âmM	1âmm	CD	O
disodium	disodium	NN	O
phenyl	phenyl	NNP	O
phosphate	phosphate	NN	O
;	;	:	O
pH	pH	NNP	O
7.5	7.5	CD	O
;	;	:	O
Lysis	lysis	NN	O
Buffer	Buffer	NNP	O
Kinase	Kinase	NNP	O
PBS	PBS	NNP	O
plus	plus	CC	O
10âmM	10âmm	CD	O
imidazole	imidazole	NN	O
and	and	CC	O
protease	protease	VB	O
inhibitors	inhibitor	NNS	O
cocktail	cocktail	NN	O
;	;	:	O
pH	pH	NNP	O
7.5	7.5	CD	O
,	,	,	O
Washing	Washing	NNP	O
Buffer	Buffer	NNP	O
Kinase	Kinase	NNP	O
PBS	PBS	NNP	O
with	with	IN	O
NaCl	NaCl	NNP	O
at	at	IN	O
300âmM	300âmm	CD	O
,	,	,	O
plus	plus	CC	O
30âmM	30âmm	CD	O
imidazole	imidazole	NN	O
,	,	,	O
1	1	CD	O
%	%	NN	O
Triton	Triton	NNP	O
X-100	X-100	NNP	O
and	and	CC	O
protease	protease	NN	O
inhibitors	inhibitor	NNS	O
cocktail	cocktail	NN	O
;	;	:	O
pH	pH	NNP	O
7.5	7.5	CD	O
,	,	,	O
Elution	Elution	NNP	O
Buffer	Buffer	NNP	O
Kinase	Kinase	NNP	O
PBS	PBS	NNP	O
plus	plus	CC	O
300âmM	300âmm	CD	O
imidazole	imidazole	NN	O
and	and	CC	O
protease	protease	VB	O
inhibitors	inhibitor	NNS	O
cocktail	cocktail	NN	O
;	;	:	O
pH	pH	NNP	O
7.5	7.5	CD	O
and	and	CC	O
Kinase	Kinase	NNP	O
Assay	Assay	NNP	O
Buffer	Buffer	NNP	O
50âmM	50âmm	CD	O
HEPES	HEPES	NNP	O
pH	pH	NNP	O
7.5	7.5	CD	O
,	,	,	O
1âmM	1âmm	CD	O
EGTA	EGTA	NNP	O
,	,	,	O
1âmM	1âmm	CD	O
EDTA	edta	NN	O
,	,	,	O
15âmM	15âmm	CD	O
Mg2	Mg2	VBD	O
,	,	,	O
0.1âmg	0.1âmg	ADD	O
/	/	SYM	O
mL	mL	NNP	O
bovine	bovine	JJ	O
seroalbumin	seroalbumin	NN	O
.	.	.	O

Leishmania	leishmania	NN	O
parasites	parasite	NNS	O
were	be	VBD	O
collected	collect	VBN	O
at	at	IN	O
late	late	JJ	O
exponential	exponential	JJ	O
growth	growth	NN	O
phase	phase	NN	O
by	by	IN	O
centrifugation	centrifugation	NN	O
at	at	IN	O
1610Ãg	1610Ãg	NNS	O
at	at	IN	O
4âÂ	4ââ	CD	O
°	°	NNS	O
C	C	NNP	O
.	.	.	O

Peritoneal	Peritoneal	NNP	O
murine	murine	NN	O
macrophages	macrophage	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
8-week	8-week	CD	O
-	-	HYPH	O
old	old	JJ	O
Balb	Balb	NNP	O
/	/	SYM	O
c	c	NNP	O
mice	mouse	NNS	O
previously	previously	RB	O
elicited	elicit	VBN	O
by	by	IN	O
i.p	i.p	NNP	O
.	.	NNP	O

injection	injection	NN	O
with	with	IN	O
1âmL	1âml	CD	O
of	of	IN	O
10	10	CD	O
%	%	NN	O
thioglycollate	thioglycollate	NN	O
medium	medium	NN	O
three	three	CD	O
days	day	NNS	O
prior	prior	RB	O
to	to	IN	O
extraction	extraction	NN	O
.	.	.	O

Macrophages	macrophage	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
peritoneal	peritoneal	JJ	O
washing	washing	NN	O
10âmL	10âml	CD	O
PBS	PBS	NNP	O
,	,	,	O
4âÂ	4ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

After	after	IN	O
extraction	extraction	NN	O
,	,	,	O
macrophages	macrophage	NNS	O
were	be	VBD	O
maintained	maintain	VBN	O
in	in	IN	O
RPMI	RPMI	NNP	O
1640-HIFCS	1640-hifcs	CD	O
at	at	IN	O
37âÂ	37âÂ	NNP	O
°	°	,	O
C	C	NNP	O
and	and	CC	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
animal	animal	NN	O
procedures	procedure	NNS	O
were	be	VBD	O
approved	approve	VBN	O
by	by	IN	O
the	the	DT	O
welfare	welfare	NN	O
animal	animal	NNP	O
ethical	ethical	JJ	O
Committee	Committee	NNP	O
of	of	IN	O
the	the	DT	O
CSIC	CSIC	NNP	O
and	and	CC	O
the	the	DT	O
Autonomous	Autonomous	NNP	O
Government	Government	NNP	O
of	of	IN	O
Madrid	Madrid	NNP	O
and	and	CC	O
followed	follow	VBD	O
the	the	DT	O
3âR	3âR	NNS	O
principle	principle	NN	O
.	.	.	O

Leishmania	Leishmania	NNP	O
parasites	parasite	NNS	O
were	be	VBD	O
resuspended	resuspend	VBN	O
with	with	IN	O
the	the	DT	O
corresponding	corresponding	JJ	O
drug	drug	NN	O
concentration	concentration	NN	O
at	at	IN	O
2âÃâ106	2âãâ106	CD	O
parasites	parasite	NNS	O
/	/	SYM	O
mL	ml	NN	O
in	in	IN	O
their	-PRON-	PRP$	O
respective	respective	JJ	O
growth	growth	NN	O
media	medium	NNS	O
in	in	IN	O
96	96	CD	O
microwell	microwell	NN	O
plates	plate	NNS	O
200âÂµL	200ââµl	CD	O
/	/	SYM	O
well	well	UH	O
.	.	.	O

The	the	DT	O
parasites	parasite	NNS	O
were	be	VBD	O
allowed	allow	VBN	O
to	to	TO	O
growth	growth	VB	O
for	for	IN	O
72âh	72âh	CD	O
at	at	IN	O
26âÂ	26ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
promastigotes	promastigote	NNS	O
and	and	CC	O
96âh	96âh	CD	O
at	at	IN	O
32âÂ	32ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
axenic	axenic	JJ	O
amastigotes	amastigote	NNS	O
.	.	.	O

Afterwards	afterwards	RB	O
,	,	,	O
inhibition	inhibition	NN	O
of	of	IN	O
proliferation	proliferation	NN	O
was	be	VBD	O
measured	measure	VBN	O
by	by	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
MTT	MTT	NNP	O
reduction	reduction	NN	O
by	by	IN	O
the	the	DT	O
parasites	parasite	NNS	O
.	.	.	O

To	to	IN	O
this	this	DT	O
end	end	NN	O
,	,	,	O
MTT	MTT	NNP	O
3â-2,5-diphenyltetrazolium	3â-2,5-diphenyltetrazolium	CD	O
bromide	bromide	NN	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
each	each	DT	O
well	well	RB	O
0.5âmg	0.5âmg	NNS	O
/	/	SYM	O
mL	mL	NNP	O
,	,	,	O
final	final	JJ	O
concentration	concentration	NN	O
.	.	.	O

MTT	MTT	NNP	O
reduction	reduction	NN	O
was	be	VBD	O
allowed	allow	VBN	O
to	to	TO	O
proceed	proceed	VB	O
for	for	IN	O
2âh	2âh	CD	O
at	at	IN	O
the	the	DT	O
respective	respective	JJ	O
temperature	temperature	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
formazan	formazan	NNS	O
solubilised	solubilise	VBN	O
by	by	IN	O
addition	addition	NN	O
of	of	IN	O
50âÂµL	50ââµl	CD	O
/	/	SYM	O
well	well	NN	O
of	of	IN	O
10	10	CD	O
%	%	NN	O
SDS	sds	NN	O
.	.	.	O

Afterwards	afterwards	RB	O
,	,	,	O
the	the	DT	O
plate	plate	NN	O
was	be	VBD	O
read	read	VBN	O
at	at	IN	O
595ânm	595ânm	CD	O
in	in	IN	O
a	a	DT	O
BioRad	BioRad	NNP	O
Microplate	Microplate	NNP	O
-	-	HYPH	O
reader	reader	NN	O
,	,	,	O
model	model	NN	O
680	680	CD	O
.	.	.	O

For	for	IN	O
peritoneal	peritoneal	JJ	O
macrophages	macrophage	NNS	O
,	,	,	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
seeded	seed	VBN	O
in	in	IN	O
96	96	CD	O
microwell	microwell	NN	O
plates	plate	NNS	O
at	at	IN	O
1âÃâ105	1âãâ105	CD	O
cells	cell	NNS	O
/	/	SYM	O
well	well	RB	O
and	and	CC	O
incubated	incubate	VBD	O
37âÂ	37âÂ	NNP	O
°	°	,	O
C	C	NNP	O
,	,	,	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
with	with	IN	O
the	the	DT	O
drug	drug	NN	O
for	for	IN	O
48âh	48âh	CD	O
.	.	.	O

The	the	DT	O
toxicity	toxicity	NN	O
was	be	VBD	O
evaluated	evaluate	VBN	O
by	by	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
MTT	MTT	NNP	O
reduction	reduction	NN	O
as	as	IN	O
above	above	RB	O
.	.	.	O

Samples	sample	NNS	O
were	be	VBD	O
made	make	VBN	O
by	by	IN	O
triplicate	triplicate	NN	O
and	and	CC	O
assays	assay	NNS	O
were	be	VBD	O
repeated	repeat	VBN	O
at	at	IN	O
least	least	RBS	O
twice	twice	RB	O
.	.	.	O

EC50	EC50	NNP	O
was	be	VBD	O
calculated	calculate	VBN	O
using	use	VBG	O
the	the	DT	O
statistical	statistical	JJ	O
module	module	NN	O
of	of	IN	O
SigmaPlot	SigmaPlot	NNP	O
v11.0	v11.0	NNP	O
software	software	NN	O
.	.	.	O

The	the	DT	O
LdGSK-3s	ldgsk-3s	JJ	O
gene	gene	NN	O
was	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
pTriEx-1.1-LdGSK-3s	ptriex-1.1-ldgsk-3s	DT	O
expression	expression	NN	O
vector	vector	NN	B
and	and	CC	O
cloned	clone	VBD	O
into	into	IN	O
the	the	DT	O
plasmid	plasmid	NNP	O
pET28	pET28	NNP	O
aby	aby	NNP	O
digestion	digestion	NN	O
with	with	IN	O
NcoI	NcoI	NNP	O
and	and	CC	O
XhoI	XhoI	NNP	O
and	and	CC	O
further	further	JJ	O
ligation	ligation	NN	O
with	with	IN	O
the	the	DT	O
T4	T4	NNP	O
DNA	DNA	NNP	O
ligase	ligase	NN	O
to	to	TO	O
obtain	obtain	VB	O
the	the	DT	O
pET28a	pet28a	NN	O
-	-	HYPH	O
LdGSK-3s	ldgsk-3s	JJ	O
recombinant	recombinant	JJ	O
plasmid	plasmid	NN	O
.	.	.	O

E.	E.	NNP	O
coli	coli	NNS	O
BL21was	BL21was	NNP	O
electroporated	electroporate	VBD	O
25âÂµF	25ââµf	CD	O
,	,	,	O
2.5âkV	2.5âkv	CD	O
,	,	,	O
200	200	CD	O
Î	î	NN	O
©	©	NNP	O
,	,	,	O
0.2âcm	0.2âcm	CD	O
cuvettes	cuvette	NNS	O
with	with	IN	O
this	this	DT	O
plasmid	plasmid	NN	O
.	.	.	O

Transformants	transformant	NNS	O
were	be	VBD	O
incubated	incubate	VBN	O
2âh	2âh	CD	O
,	,	,	O
37âÂ	37âÂ	NNP	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
LB	LB	NNP	O
medium	medium	NN	O
supplemented	supplement	VBN	O
with	with	IN	O
10âmM	10âmm	CD	O
MgCl2	mgcl2	CD	O
,	,	,	O
10âmM	10âmm	CD	O
MgSO4	MgSO4	NNP	O
and	and	CC	O
20âmM	20âmm	CD	O
D	d	NN	O
-	-	HYPH	O
glucose	glucose	NN	O
and	and	CC	O
further	further	RB	O
selected	select	VBN	O
in	in	IN	O
LB	LB	NNP	O
agar	agar	NN	O
plates	plate	NNS	O
supplemented	supplement	VBN	O
with	with	IN	O
kanamycin	kanamycin	NNS	O
at	at	IN	O
50âÂµg	50âÂµg	NNP	O
/	/	SYM	O
mL.	mL.	NNP	O
The	the	DT	O
new	new	JJ	O
plasmid	plasmid	NN	O
construct	construct	NN	O
was	be	VBD	O
confirmed	confirm	VBN	O
by	by	IN	O
automated	automate	VBN	O
sequencing	sequencing	NN	O
.	.	.	O

Expression	expression	NN	O
of	of	IN	O
LdGSK-3	LdGSK-3	NNP	O
in	in	IN	O
E.	E.	NNP	O
coli	coli	NNS	O
BL21(pET-28a	BL21(pET-28a	NNP	O
-	-	HYPH	O
LdGSK-3	LdGSK-3	NNP	O
,	,	,	O
O.	O.	NNP	O
D.595nm=	D.595nm=	NNP	O
0.6	0.6	CD	O
was	be	VBD	O
induced	induce	VBN	O
with	with	IN	O
1âmM	1âmm	CD	O
IPTG	IPTG	NNP	O
3âh	3âh	CD	O
at	at	IN	O
37âÂ	37âÂ	NNP	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
selected	select	VBN	O
kanamycin	kanamycin	NNP	O
LB	LB	NNP	O
media	media	NN	O
in	in	IN	O
agitation	agitation	NN	O
.	.	.	O

Culture	culture	NN	O
was	be	VBD	O
centrifuged	centrifuge	VBN	O
at	at	IN	O
10,800Ãg	10,800ãg	CD	O
30âmin	30âmin	NN	O
,	,	,	O
4âÂ	4ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

Afterwards	afterwards	RB	O
the	the	DT	O
pellet	pellet	NN	O
was	be	VBD	O
resuspended	resuspend	VBN	O
in	in	IN	O
Lysis	Lysis	NNP	O
Buffer	Buffer	NNP	O
,	,	,	O
and	and	CC	O
disrupted	disrupt	VBD	O
in	in	IN	O
a	a	DT	O
French	french	JJ	O
Press	Press	NNP	O
.	.	.	O

Then	then	RB	O
,	,	,	O
0.1	0.1	CD	O
%	%	NN	O
Triton	Triton	NNP	O
X-100	X-100	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
the	the	DT	O
lysate	lysate	NN	O
,	,	,	O
and	and	CC	O
further	further	RB	O
incubated	incubate	VBD	O
for	for	IN	O
30âmin	30âmin	NN	O
at	at	IN	O
4âÂ	4ââ	CD	O
°	°	,	O
C	C	NNP	O
with	with	IN	O
shaking	shake	VBG	O
.	.	.	O

The	the	DT	O
non	non	JJ	O
-	-	JJ	O
soluble	soluble	JJ	O
material	material	NN	O
was	be	VBD	O
removed	remove	VBN	O
by	by	IN	O
centrifugation	centrifugation	NN	O
38,730Ãg	38,730ãg	CD	O
,	,	,	O
30âmin	30âmin	NN	O
,	,	,	O
4âÂ	4ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

The	the	DT	O
supernatant	supernatant	JJ	O
was	be	VBD	O
loaded	load	VBN	O
into	into	IN	O
an	an	DT	O
equilibrated	equilibrated	JJ	O
Ni	Ni	NNP	O
-	-	HYPH	O
column	column	NN	O
HisTrapTM	HisTrapTM	NNP	O
FF	FF	NNP	O
crude	crude	NN	O
5âmL	5âml	NN	O
,	,	,	O
Merck	Merck	NNP	O
,	,	,	O
Ref	Ref	NNP	O
.	.	NNP	O

17â5286	17â5286	CD	O
-	-	SYM	O
01	01	CD	O
.	.	.	O

The	the	DT	O
non	non	JJ	O
-	-	JJ	O
bound	bound	JJ	O
material	material	NN	O
was	be	VBD	O
removed	remove	VBN	O
by	by	IN	O
Washing	Washing	NNP	O
Buffer	Buffer	NNP	O
and	and	CC	O
LdGSK-3	LdGSK-3	NNP	O
was	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
the	the	DT	O
column	column	NN	O
using	use	VBG	O
the	the	DT	O
Elution	Elution	NNP	O
Buffer	Buffer	NNP	O
.	.	.	O

The	the	DT	O
resulting	result	VBG	O
fractions	fraction	NNS	O
were	be	VBD	O
kept	keep	VBN	O
at	at	IN	O
â80âÂ	â80ââ	NN	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
15	15	CD	O
%	%	NN	O
glycerol	glycerol	NN	O
.	.	.	O

GSK-3	gsk-3	JJ	O
activity	activity	NN	O
was	be	VBD	O
measured	measure	VBN	O
using	use	VBG	O
the	the	DT	O
Kinase	Kinase	NNP	O
GloTM	GloTM	NNP	O
protocol	protocol	NN	O
described	describe	VBN	O
below	below	IN	O
.	.	.	O

Fractions	fraction	NNS	O
and	and	CC	O
samples	sample	NNS	O
from	from	IN	O
the	the	DT	O
different	different	JJ	O
purification	purification	NN	O
steps	step	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
for	for	IN	O
kinase	kinase	NN	O
activity	activity	NN	O
,	,	,	O
protein	protein	NN	O
content	content	NN	O
evaluated	evaluate	VBN	O
by	by	IN	O
Bradford	Bradford	NNP	O
reagent	reagent	NN	O
,	,	,	O
and	and	CC	O
their	-PRON-	PRP$	O
protein	protein	NN	O
pattern	pattern	NN	O
obtained	obtain	VBN	O
by	by	IN	O
SDS	SDS	NNP	O
-	-	HYPH	O
PAGE	PAGE	NNP	O
electrophoresis	electrophoresis	NN	O
on	on	IN	O
a	a	DT	O
10	10	CD	O
%	%	NN	O
polyacrylamide	polyacrylamide	NN	O
gel	gel	NN	O
.	.	.	O

Fractions	fraction	NNS	O
with	with	IN	O
the	the	DT	O
highest	high	JJS	O
GSK-3	GSK-3	NNP	O
activity	activity	NN	O
were	be	VBD	O
pooled	pool	VBN	O
and	and	CC	O
dialysed	dialyse	VBN	O
using	use	VBG	O
an	an	DT	O
Amicon	Amicon	NNP	O
cell	cell	NN	O
filtration	filtration	NN	O
30âkDa	30âkda	CD	O
cut	cut	VBN	O
-	-	HYPH	O
off	off	RP	O
membrane	membrane	NN	O
using	use	VBG	O
Kinase	Kinase	NNP	O
PBS	PBS	NNP	O
as	as	IN	O
washing	washing	NN	O
buffer	buffer	NN	O
.	.	.	O

LdGSK-3	LdGSK-3	NNP	O
was	be	VBD	O
quantified	quantify	VBN	O
after	after	IN	O
ultracentrifugation	ultracentrifugation	NN	O
147,000Ãg	147,000Ãg	NNS	O
,	,	,	O
1âh	1âh	CD	O
,	,	,	O
4âÂ	4ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
filtrated	filtrate	VBD	O
through	through	IN	O
a	a	DT	O
0.22âÂµm	0.22âÂµm	NNP	O
nitrocellulose	nitrocellulose	NN	O
filter	filter	NN	O
and	and	CC	O
preserved	preserve	VBD	O
at	at	IN	O
â80âÂ	â80âÂ	NNS	O
°	°	,	O
C	C	NNP	O
.	.	.	O

Compounds	compound	NNS	O
were	be	VBD	O
tested	test	VBN	O
against	against	IN	O
20âng	20âng	CD	O
of	of	IN	O
purified	purify	VBN	O
LdGSK-3	LdGSK-3	NNP	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
25âÂµM	25ââµm	CD	O
Phosphoglycogen	Phosphoglycogen	NNP	O
Synthase	Synthase	NNP	O
Peptide-2	Peptide-2	NNP	O
Millipore	Millipore	NNP	O
,	,	,	O
Ref	Ref	NNP	O
.	.	.	O

12â241	12â241	CD	O
and	and	CC	O
1âÂµM	1ââµm	CD	O
ATP	atp	NN	O
in	in	IN	O
Kinase	Kinase	NNP	O
Assay	Assay	NNP	O
Buffer	Buffer	NNP	O
in	in	IN	O
96-well	96-well	CD	O
black	black	JJ	O
plates	plate	NNS	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
allowed	allow	VBN	O
to	to	TO	O
proceed	proceed	VB	O
for	for	IN	O
30âmin	30âmin	NN	O
at	at	IN	O
30âÂ	30âÂ	NNP	O
°	°	,	O
C	C	NNP	O
,	,	,	O
then	then	RB	O
it	-PRON-	PRP	O
was	be	VBD	O
incubated	incubate	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
another	another	DT	O
10âmin	10âmin	NN	O
after	after	IN	O
addition	addition	NN	O
of	of	IN	O
Kinase	Kinase	NNP	O
Glo	Glo	NNP	O
reagents	reagent	VBZ	O
.	.	.	O

ATP	atp	NN	O
consumption	consumption	NN	O
by	by	IN	O
LdGSK-3	LdGSK-3	NNP	O
was	be	VBD	O
measured	measure	VBN	O
indirectly	indirectly	RB	O
through	through	IN	O
end	end	NN	O
-	-	HYPH	O
point	point	NN	O
luminescence	luminescence	NN	O
measurement	measurement	NN	O
of	of	IN	O
each	each	DT	O
well	well	NN	O
in	in	IN	O
a	a	DT	O
Varioskan	Varioskan	NNP	O
Flash	Flash	NNP	O
microplate	microplate	NN	O
reader	reader	NN	O
.	.	.	O

All	all	DT	O
available	available	JJ	O
sequences	sequence	NNS	O
in	in	IN	O
the	the	DT	O
Uniprot	Uniprot	NNP	O
database	database	NN	B
corresponding	correspond	VBG	O
to	to	IN	O
Leishmania	Leishmania	NNP	O
spp	spp	NN	O
.	.	.	O

GSK-3	GSK-3	NNP	O
and	and	CC	O
human	human	JJ	O
GSK-3	GSK-3	NNP	O
were	be	VBD	O
retrieved	retrieve	VBN	O
.	.	.	O

First	first	RB	O
,	,	,	O
as	as	IN	O
the	the	DT	O
only	only	JJ	O
GSK-3	GSK-3	NNP	O
crystal	crystal	NN	O
structure	structure	NN	O
available	available	JJ	O
in	in	IN	O
Leishmania	Leishmania	NNP	O
is	be	VBZ	O
from	from	IN	O
L.	L.	NNP	O
major	major	NN	O
,	,	,	O
this	this	DT	O
sequence	sequence	NN	O
was	be	VBD	O
compared	compare	VBN	O
with	with	IN	O
that	that	DT	O
from	from	IN	O
L.	L.	NNP	O
donovani	donovani	NNP	O
,	,	,	O
and	and	CC	O
further	further	RB	O
extended	extend	VBN	O
to	to	IN	O
the	the	DT	O
rest	rest	NN	O
of	of	IN	O
GSK-3	GSK-3	NNP	O
sequences	sequence	NNS	O
available	available	JJ	O
for	for	IN	O
Leishmania	Leishmania	NNP	O
.	.	.	O

In	in	IN	O
all	all	DT	O
cases	case	NNS	O
,	,	,	O
sequence	sequence	NN	O
alignments	alignment	NNS	O
were	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
Clustal	clustal	JJ	O
omega	omega	NN	O
software	software	NN	O
and	and	CC	O
default	default	NN	O
parameters	parameter	NNS	O
were	be	VBD	O
selected	select	VBN	B
.	.	.	O

For	for	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
this	this	DT	O
work	work	NN	O
,	,	,	O
all	all	PDT	O
the	the	DT	O
compounds	compound	NNS	O
used	use	VBN	O
were	be	VBD	O
prepared	prepare	VBN	O
and	and	CC	O
converted	convert	VBN	O
into	into	IN	O
3âD	3âd	JJ	O
structures	structure	NNS	O
for	for	IN	O
computational	computational	JJ	O
studies	study	NNS	O
applying	apply	VBG	O
Ligprep	Ligprep	NNP	O
tool	tool	NN	B
,	,	,	O
a	a	DT	O
module	module	NN	O
of	of	IN	O
the	the	DT	O
SchrÃ¶dinger	SchrÃ¶dinger	NNP	O
software	software	NN	O
package	package	NN	O
.	.	.	O

The	the	DT	O
most	most	RBS	O
reliable	reliable	JJ	O
ionisation	ionisation	NN	O
states	state	NNS	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
were	be	VBD	O
optimised	optimise	VBN	O
at	at	IN	O
pH	pH	NNP	O
7.3	7.3	CD	O
as	as	IN	O
assigned	assign	VBN	O
by	by	IN	O
the	the	DT	O
Epik	epik	JJ	O
module	module	NN	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
no	no	DT	O
tautomers	tautomer	NNS	O
were	be	VBD	O
generated	generate	VBN	O
and	and	CC	O
all	all	PDT	O
the	the	DT	O
compounds	compound	NNS	O
were	be	VBD	O
desalted	desalt	VBN	O
.	.	.	O

During	during	IN	O
this	this	DT	O
process	process	NN	O
,	,	,	O
the	the	DT	O
search	search	NN	O
was	be	VBD	O
restricted	restrict	VBN	O
to	to	IN	O
the	the	DT	O
compound	compound	NN	O
with	with	IN	O
the	the	DT	O
low	low	JJ	O
energy	energy	NN	O
ring	ring	NN	O
conformation	conformation	NN	O
and	and	CC	O
its	-PRON-	PRP$	O
most	most	RBS	O
probable	probable	JJ	O
stereoisomer	stereoisomer	NN	O
as	as	IN	O
found	find	VBN	O
by	by	IN	O
the	the	DT	O
programme	programme	NN	O
.	.	.	O

As	as	IN	O
a	a	DT	O
final	final	JJ	O
step	step	NN	O
,	,	,	O
OPLS	OPLS	NNP	O
2005	2005	CD	O
force	force	NN	O
field	field	NN	O
was	be	VBD	O
applied	apply	VBN	O
in	in	IN	O
the	the	DT	O
energy	energy	NN	O
minimisation	minimisation	NN	O
process	process	NN	O
of	of	IN	O
the	the	DT	O
generated	generate	VBN	O
3âD	3âd	CD	O
conformers	conformer	NNS	B
.	.	.	O

The	the	DT	O
crystal	crystal	NN	O
structure	structure	NN	O
3E3P	3e3p	CD	O
of	of	IN	O
LmjGSK-3	LmjGSK-3	NNP	B
was	be	VBD	O
retrieved	retrieve	VBN	O
from	from	IN	O
the	the	DT	O
PDB	PDB	NNP	O
.	.	.	O

However	however	RB	O
,	,	,	O
in	in	IN	O
this	this	DT	O
crystallographic	crystallographic	JJ	O
model	model	NN	O
the	the	DT	O
structure	structure	NN	O
of	of	IN	O
the	the	DT	O
decapeptide	decapeptide	NN	O
located	locate	VBN	O
at	at	IN	O
the	the	DT	O
upper	upper	JJ	O
part	part	NN	O
of	of	IN	O
the	the	DT	O
ATP	ATP	NNP	O
binding	bind	VBG	O
pocket	pocket	NN	O
was	be	VBD	O
absent	absent	JJ	O
.	.	.	O

This	this	DT	O
gap	gap	NN	O
was	be	VBD	O
modelled	model	VBN	O
with	with	IN	O
the	the	DT	O
Modeller	Modeller	NNP	O
programe	programe	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
whole	whole	JJ	O
protein	protein	NN	O
was	be	VBD	O
subsequently	subsequently	RB	O
prepared	prepare	VBN	O
using	use	VBG	O
the	the	DT	O
Protein	Protein	NNP	O
Preparation	Preparation	NNP	O
Wizard	Wizard	NNP	O
tool	tool	NN	O
implemented	implement	VBN	O
on	on	IN	O
Maestro	Maestro	NNP	B
,	,	,	B
.	.	.	O

Hydrogens	hydrogen	NNS	O
were	be	VBD	O
added	add	VBN	O
and	and	CC	O
the	the	DT	O
water	water	NN	O
molecules	molecule	NNS	O
removed	remove	VBD	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
residues	residue	NNS	O
were	be	VBD	O
optimised	optimise	VBN	O
according	accord	VBG	O
to	to	IN	O
their	-PRON-	PRP$	O
pKa	pKa	NNS	O
and	and	CC	O
their	-PRON-	PRP$	O
corresponding	correspond	VBG	O
protonation	protonation	NN	O
state	state	NN	O
as	as	IN	O
calculated	calculate	VBN	O
at	at	IN	O
a	a	DT	O
physiological	physiological	JJ	O
pH	pH	NNP	O
of	of	IN	O
7.3	7.3	CD	O
.	.	.	O

Automated	automate	VBN	O
docking	docking	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
assess	assess	VB	O
the	the	DT	O
appropriate	appropriate	JJ	O
binding	binding	JJ	O
orientations	orientation	NNS	O
and	and	CC	O
conformations	conformation	NNS	O
of	of	IN	O
the	the	DT	O
ligands	ligand	NNS	O
.	.	.	O

To	to	IN	O
this	this	DT	O
end	end	NN	O
,	,	,	O
a	a	DT	O
Lamarckian	lamarckian	JJ	O
genetic	genetic	JJ	O
algorithm	algorithm	NN	O
method	method	NN	O
of	of	IN	O
the	the	DT	O
AutoDock	AutoDock	NNP	O
4.2	4.2	CD	O
programme	programme	NN	O
was	be	VBD	O
employed	employ	VBN	B
,	,	,	B
.	.	.	O

For	for	IN	O
docking	dock	VBG	O
calculations	calculation	NNS	O
,	,	,	O
Gasteiger	Gasteiger	NNP	O
charges	charge	NNS	O
were	be	VBD	O
added	add	VBN	O
to	to	IN	O
the	the	DT	O
ligands	ligand	NNS	O
and	and	CC	O
to	to	IN	O
the	the	DT	O
protein	protein	NN	O
,	,	,	O
rotatable	rotatable	JJ	O
bonds	bond	NNS	O
were	be	VBD	O
set	set	VBN	O
by	by	IN	O
AutoDock	AutoDock	NNP	O
tools	tool	NNS	O
,	,	,	O
and	and	CC	O
all	all	DT	O
accepted	accept	VBN	O
torsions	torsion	NNS	O
were	be	VBD	O
allowed	allow	VBN	O
to	to	IN	O
the	the	DT	O
ligand	ligand	NN	O
.	.	.	O

For	for	IN	O
the	the	DT	O
blind	blind	JJ	O
docking	docking	NN	O
,	,	,	O
a	a	DT	O
maximum	maximum	JJ	O
grid	grid	NN	O
of	of	IN	O
126âÃâ126âÃâ126	126âãâ126âãâ126	CD	O
points	point	NNS	O
and	and	CC	O
a	a	DT	O
grid	grid	NN	O
-	-	HYPH	O
point	point	NN	O
spacing	spacing	NN	O
of	of	IN	O
0.375âÃ	0.375âÃ	NNP	O
was	be	VBD	O
set	set	VBN	O
up	up	RP	O
to	to	TO	O
include	include	VB	O
the	the	DT	O
whole	whole	JJ	O
surface	surface	NN	O
of	of	IN	O
the	the	DT	O
protein	protein	NN	O
.	.	.	O

The	the	DT	O
macromolecule	macromolecule	NN	O
centre	centre	NN	O
was	be	VBD	O
selected	select	VBN	O
as	as	IN	O
the	the	DT	O
centroid	centroid	NN	O
of	of	IN	O
the	the	DT	O
grid	grid	NN	O
.	.	.	O

When	when	WRB	O
the	the	DT	O
docking	docking	NN	O
was	be	VBD	O
focussed	focusse	VBN	O
in	in	IN	O
a	a	DT	O
specific	specific	JJ	O
pocket	pocket	NN	O
,	,	,	O
grid	grid	NN	O
maps	map	NNS	O
with	with	IN	O
a	a	DT	O
grid	grid	NN	O
box	box	NN	O
size	size	NN	O
of	of	IN	O
50âÃâ50âÃâ50	50âãâ50âãâ50	JJ	O
points	point	NNS	O
and	and	CC	O
a	a	DT	O
grid	grid	NN	O
-	-	HYPH	O
point	point	NN	O
spacing	spacing	NN	O
of	of	IN	O
0.375âÃ	0.375âã	CD	O
were	be	VBD	O
used	use	VBN	O
.	.	.	O

The	the	DT	O
docking	docking	NN	O
protocol	protocol	NN	O
consisted	consist	VBD	O
of	of	IN	O
200	200	CD	O
independent	independent	JJ	O
Genetic	Genetic	NNP	O
Algorithm	Algorithm	NNP	O
runs	run	NNS	O
,	,	,	O
population	population	NN	O
size	size	NN	O
of	of	IN	O
150	150	CD	O
,	,	,	O
a	a	DT	O
maximum	maximum	JJ	O
evaluation	evaluation	NN	O
number	number	NN	O
of	of	IN	O
250,000Â	250,000â	CD	O
and	and	CC	O
default	default	NN	O
values	value	NNS	O
for	for	IN	O
the	the	DT	O
remaining	remain	VBG	O
parameters	parameter	NNS	O
.	.	.	O

For	for	IN	O
covalent	covalent	NN	O
docking	docking	NN	O
,	,	,	O
a	a	DT	O
special	special	JJ	O
map	map	NN	O
for	for	IN	O
the	the	DT	O
attachment	attachment	NN	O
site	site	NN	O
of	of	IN	O
the	the	DT	O
covalent	covalent	NN	O
ligand	ligand	NNP	O
was	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
the	the	DT	O
grid	grid	NN	O
-	-	HYPH	O
based	base	VBN	O
approach	approach	NN	O
.	.	.	O

A	a	DT	O
Gaussian	gaussian	JJ	O
function	function	NN	O
is	be	VBZ	O
constructed	construct	VBN	O
with	with	IN	O
zero	zero	CD	O
energy	energy	NN	O
at	at	IN	O
the	the	DT	O
site	site	NN	O
of	of	IN	O
attachment	attachment	NN	O
,	,	,	O
and	and	CC	O
steep	steep	JJ	O
energetic	energetic	JJ	O
penalties	penalty	NNS	O
at	at	IN	O
the	the	DT	O
surrounding	surround	VBG	O
areas	area	NNS	O
.	.	.	O

Docking	docking	NN	O
analysis	analysis	NN	O
was	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
a	a	DT	O
specific	specific	JJ	O
atom	atom	NN	O
type	type	NN	O
for	for	IN	O
the	the	DT	O
atom	atom	NN	O
that	that	WDT	O
forms	form	VBZ	O
the	the	DT	O
covalent	covalent	NN	O
linkage	linkage	NN	O
.	.	.	O

Cys169	cys169	CD	O
was	be	VBD	O
selected	select	VBN	O
as	as	IN	O
the	the	DT	O
centroid	centroid	NN	O
of	of	IN	O
the	the	DT	O
grid	grid	NN	O
and	and	CC	O
its	-PRON-	PRP$	O
sulphur	sulphur	NN	O
atom	atom	NN	O
defined	define	VBN	O
as	as	IN	O
the	the	DT	O
site	site	NN	O
of	of	IN	O
covalent	covalent	NN	O
binding	bind	VBG	O
.	.	.	O

In	in	IN	O
all	all	DT	O
cases	case	NNS	O
,	,	,	O
visual	visual	JJ	O
inspection	inspection	NN	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
for	for	IN	O
the	the	DT	O
final	final	JJ	O
best	good	JJS	O
docked	dock	VBN	O
clusters	cluster	NNS	O
,	,	,	O
defined	define	VBN	O
as	as	IN	O
aâ<â2.0âÃ	aâ<â2.0âÃ	NNS	O
RMSD	rmsd	JJ	O
default	default	NN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
binding	bind	VBG	O
energies	energy	NNS	O
and	and	CC	O
the	the	DT	O
relative	relative	JJ	O
population	population	NN	O
as	as	IN	O
provided	provide	VBN	O
by	by	IN	O
Autodock	Autodock	NNP	O
.	.	.	O

Induced	induced	JJ	O
Fit	Fit	NNP	O
Docking	Docking	NNP	B
,	,	,	B
is	be	VBZ	O
based	base	VBN	O
on	on	IN	O
fitting	fit	VBG	O
the	the	DT	O
ligand	ligand	NN	O
into	into	IN	O
the	the	DT	O
protein	protein	NN	O
binding	bind	VBG	O
site	site	NN	O
allowing	allow	VBG	O
changes	change	NNS	O
in	in	IN	O
the	the	DT	O
geometry	geometry	NN	O
of	of	IN	O
the	the	DT	O
nearby	nearby	JJ	O
residues	residue	NNS	O
,	,	,	O
mostly	mostly	RB	O
in	in	IN	O
the	the	DT	O
side	side	NN	O
chains	chain	NNS	O
.	.	.	O

For	for	IN	O
this	this	DT	O
purpose	purpose	NN	O
,	,	,	O
Prime	Prime	NNP	B
predicts	predict	VBZ	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
structure	structure	NN	O
and	and	CC	O
minimising	minimise	VBG	O
the	the	DT	O
overall	overall	JJ	O
energy	energy	NN	O
of	of	IN	O
the	the	DT	O
protein	protein	NN	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
each	each	DT	O
ligand	ligand	NN	O
is	be	VBZ	O
re	re	JJ	O
-	-	VBN	O
docked	docked	JJ	O
into	into	IN	O
its	-PRON-	PRP$	O
corresponding	correspond	VBG	O
low	low	JJ	O
energy	energy	NN	O
protein	protein	NN	O
structures	structure	NNS	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
complexes	complex	NNS	O
rank	rank	VBP	O
according	accord	VBG	O
to	to	IN	O
docking	docking	NN	O
score	score	NN	O
.	.	.	O

XP	XP	NNP	O
mode	mode	NN	O
was	be	VBD	O
used	use	VBN	O
in	in	IN	O
a	a	DT	O
standard	standard	JJ	O
protocol	protocol	NN	O
and	and	CC	O
no	no	DT	O
constraints	constraint	NNS	O
were	be	VBD	O
set	set	VBN	O
,	,	,	O
residues	residue	NNS	O
were	be	VBD	O
optimised	optimise	VBN	O
to	to	IN	O
5.0âÃ	5.0âã	CD	O
of	of	IN	O
the	the	DT	O
ligand	ligand	NN	O
poses	pose	VBZ	O
while	while	IN	O
the	the	DT	O
rest	rest	NN	O
of	of	IN	O
the	the	DT	O
parameters	parameter	NNS	O
were	be	VBD	O
set	set	VBN	O
as	as	IN	O
default	default	NN	O
.	.	.	O

The	the	DT	O
best	good	JJS	O
structures	structure	NNS	O
were	be	VBD	O
selected	select	VBN	O
to	to	TO	O
carry	carry	VB	O
out	out	RP	O
further	further	JJ	O
docking	docking	NN	O
studies	study	NNS	O
.	.	.	O

An	an	DT	O
enzymatic	enzymatic	JJ	O
and	and	CC	O
phenotypic	phenotypic	JJ	O
screening	screening	NN	O
of	of	IN	O
a	a	DT	O
selected	select	VBN	O
set	set	NN	O
of	of	IN	O
24	24	CD	O
hGSK-3Î²	hgsk-3î²	CD	O
inhibitors	inhibitor	NNS	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
find	find	VB	O
potential	potential	JJ	O
drugs	drug	NNS	O
for	for	IN	O
leishmaniasis	leishmaniasis	NN	O
.	.	.	O

These	these	DT	O
heterocyclic	heterocyclic	JJ	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
designed	design	VBN	O
and	and	CC	O
synthesised	synthesise	VBN	O
in	in	IN	O
our	-PRON-	PRP$	O
laboratory	laboratory	NN	O
and	and	CC	O
chosen	choose	VBN	O
according	accord	VBG	O
to	to	IN	O
their	-PRON-	PRP$	O
chemical	chemical	JJ	O
diversity	diversity	NN	O
and	and	CC	O
binding	bind	VBG	O
mode	mode	NN	O
to	to	IN	O
hGSK-3Î²	hgsk-3î²	CD	O
enzyme	enzyme	NNS	O
as	as	IN	O
previously	previously	RB	O
reported	report	VBN	O
.	.	.	O

The	the	DT	O
selection	selection	NN	O
included	include	VBD	O
thiadiazole	thiadiazole	NNP	O
,	,	,	O
thiophene	thiophene	NNP	O
,	,	,	O
quinoline	quinoline	NNP	O
,	,	,	O
thiazole	thiazole	NN	O
and	and	CC	O
maleimide	maleimide	NN	O
derivatives	derivative	NNS	O
,	,	,	O
acting	act	VBG	O
as	as	IN	O
ATP	atp	NN	O
-	-	HYPH	O
non	non	JJ	O
competitive	competitive	JJ	B
,	,	,	O
substrate	substrate	VB	O
competitive	competitive	JJ	B
,	,	,	O
allosteric	allosteric	JJ	B
,	,	,	B
,	,	,	O
and	and	CC	O
reversible	reversible	JJ	O
or	or	CC	O
irreversible	irreversible	JJ	O
ATP	atp	NN	O
-	-	HYPH	O
competitive	competitive	JJ	B
inhibitors	inhibitor	NNS	O
.	.	.	O

Notably	notably	RB	O
,	,	,	O
one	one	CD	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
tested	test	VBN	O
,	,	,	O
tideglusib	tideglusib	NNP	O
,	,	,	O
is	be	VBZ	O
under	under	IN	O
current	current	JJ	O
clinical	clinical	JJ	O
trials	trial	NNS	O
for	for	IN	O
neurological	neurological	JJ	O
disorders	disorder	NNS	B
.	.	.	O

Compounds	compound	NNS	O
1â24	1â24	CD	O
were	be	VBD	O
simultaneously	simultaneously	RB	O
evaluated	evaluate	VBN	O
against	against	IN	O
the	the	DT	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
inhibition	inhibition	NN	O
of	of	IN	O
LdGSK-3	LdGSK-3	NNP	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
in	in	IN	O
phenotypic	phenotypic	NN	O
assays	assay	NNS	O
for	for	IN	O
leishmanicidal	leishmanicidal	JJ	O
activities	activity	NNS	O
.	.	.	O

The	the	DT	O
enzyme	enzyme	NNS	O
was	be	VBD	O
expressed	express	VBN	O
and	and	CC	O
purified	purify	VBN	O
based	base	VBN	O
on	on	IN	O
a	a	DT	O
previous	previous	JJ	O
protocol	protocol	NN	O
with	with	IN	O
subtle	subtle	JJ	O
modifications	modification	NNS	B
,	,	,	O
and	and	CC	O
the	the	DT	O
enzymatic	enzymatic	JJ	O
activity	activity	NN	O
measured	measure	VBN	O
by	by	IN	O
luminescence	luminescence	NN	O
evaluation	evaluation	NN	O
of	of	IN	O
the	the	DT	O
remaining	remain	VBG	O
ATP	atp	NN	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
compounds	compound	NNS	O
were	be	VBD	O
tested	test	VBN	O
in	in	IN	O
Leishmania	Leishmania	NNP	O
cultures	culture	NNS	O
,	,	,	O
and	and	CC	O
their	-PRON-	PRP$	O
cytotoxicity	cytotoxicity	NN	O
evaluated	evaluate	VBN	O
in	in	IN	O
peritoneal	peritoneal	JJ	O
murine	murine	NN	O
macrophages	macrophage	NNS	O
.	.	.	O

After	after	IN	O
these	these	DT	O
initial	initial	JJ	O
studies	study	NNS	O
,	,	,	O
elevenÂ	elevenÂ	NNP	O
showed	show	VBD	O
a	a	DT	O
good	good	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
LdGSK-3	LdGSK-3	NNP	O
and	and	CC	O
some	some	DT	O
of	of	IN	O
them	-PRON-	PRP	O
also	also	RB	O
phenotypic	phenotypic	VBP	O
activities	activity	NNS	O
.	.	.	O

From	from	IN	O
the	the	DT	O
initial	initial	JJ	O
set	set	NN	O
,	,	,	O
eightÂ	eightÂ	NNP	O
were	be	VBD	O
selected	select	VBN	O
as	as	IN	O
representative	representative	JJ	O
members	member	NNS	O
of	of	IN	O
the	the	DT	O
different	different	JJ	O
chemical	chemical	JJ	O
families	family	NNS	O
according	accord	VBG	O
to	to	IN	O
their	-PRON-	PRP$	O
binding	bind	VBG	O
modes	mode	NNS	O
to	to	IN	O
the	the	DT	O
human	human	JJ	O
enzyme	enzyme	NNS	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
to	to	IN	O
theirÂ	theirÂ	NNP	O
biological	biological	JJ	O
activities	activity	NNS	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Table	table	NN	O
1	1	CD	O
,	,	,	O
all	all	PDT	O
the	the	DT	O
selected	select	VBN	O
compounds	compound	NNS	O
inhibited	inhibit	VBN	O
LdGSK-3	LdGSK-3	NNP	O
,	,	,	O
except	except	IN	O
quinoline	quinoline	NN	O
11	11	CD	O
and	and	CC	O
maleimide	maleimide	VBP	O
13	13	CD	O
.	.	.	O

Thiadiazolidinones	Thiadiazolidinones	NNPS	O
Â	Â	NNP	O
1	1	CD	O
and	and	CC	O
2	2	CD	O
,	,	,	O
and	and	CC	O
halomethylketones	halomethylketone	VBZ	O
5	5	CD	O
and	and	CC	O
14	14	CD	O
,	,	,	O
inhibited	inhibited	JJ	O
LdGSK-3	LdGSK-3	NNP	O
,	,	,	O
and	and	CC	O
also	also	RB	O
showed	show	VBD	O
a	a	DT	O
higher	high	JJR	O
leishmanicidal	leishmanicidal	JJ	O
activity	activity	NN	O
on	on	IN	O
axenic	axenic	JJ	O
amastigotes	amastigote	NNS	O
than	than	IN	O
on	on	IN	O
promastigotes	promastigote	NNS	O
.	.	.	O

Compounds	compound	NNS	O
3	3	CD	O
and	and	CC	O
4	4	CD	O
,	,	,	O
both	both	CC	O
5-imino-1,2,4-thiadiazoles	5-imino-1,2,4-thiadiazoles	CD	O
,	,	,	O
showed	show	VBD	O
nil	nil	NNP	O
antiparasitic	antiparasitic	JJ	O
activities	activity	NNS	O
,	,	,	O
despite	despite	IN	O
their	-PRON-	PRP$	O
significant	significant	JJ	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
inhibition	inhibition	NN	O
of	of	IN	O
the	the	DT	O
enzyme	enzyme	NNS	O
.	.	.	O

In	in	IN	O
vitro	vitro	FW	O
enzymatic	enzymatic	JJ	O
and	and	CC	O
antiparasitic	antiparasitic	JJ	O
activities	activity	NNS	O
of	of	IN	O
selected	select	VBN	O
hGSK-3Î²	hgsk-3î²	CD	O
inhibitors.aIndirubin-3â-monoxime-5-sulphonic	inhibitors.aindirubin-3â-monoxime-5-sulphonic	JJ	O
acid	acid	NN	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
reference	reference	NN	O
of	of	IN	O
the	the	DT	O
assay	assay	NN	O
:	:	:	O
IC50	ic50	NN	O
=	=	SYM	O
2.4âÂ±â0.2âÎ¼M.	2.4ââ±â0.2âî¼m.	CD	O
PMM	pmm	NN	O
:	:	:	O
peritoneal	peritoneal	JJ	O
murine	murine	NN	O
macrophages	macrophage	NNS	O
.	.	.	O

SI	si	NN	O
:	:	:	O
Specificity	Specificity	NNP	O
Index	Index	NNP	O
.	.	.	O

Compounds	compound	NNS	O
1	1	CD	O
and	and	CC	O
2	2	CD	O
are	be	VBP	O
well	well	RB	O
-	-	HYPH	O
known	know	VBN	O
members	member	NNS	O
of	of	IN	O
the	the	DT	O
non	non	JJ	O
-	-	JJ	O
ATP	atp	JJ	O
competitive	competitive	JJ	O
TDZD	TDZD	NNP	O
family	family	NN	O
of	of	IN	O
hGSK-3Î²	hgsk-3î²	CD	O
inhibitors	inhibitor	NNS	B
acting	act	VBG	O
as	as	IN	O
covalent	covalent	NN	O
inhibitors	inhibitor	NNS	O
through	through	IN	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
a	a	DT	O
disulphide	disulphide	NN	O
bond	bond	NN	O
with	with	IN	O
Cys19961	Cys19961	NNP	O
.	.	.	O

Since	since	IN	O
this	this	DT	O
Cys	Cys	NNP	O
residue	residue	NN	O
is	be	VBZ	O
conserved	conserve	VBN	O
at	at	IN	O
the	the	DT	O
entrance	entrance	NN	O
of	of	IN	O
the	the	DT	O
ATP	ATP	NNP	O
binding	bind	VBG	O
site	site	NN	O
of	of	IN	O
LdGSK-3	LdGSK-3	NNP	O
,	,	,	O
it	-PRON-	PRP	O
is	be	VBZ	O
expected	expect	VBN	O
that	that	IN	O
TDZDs	TDZDs	NNP	O
bind	bind	VB	O
the	the	DT	O
parasitic	parasitic	JJ	O
enzyme	enzyme	NNS	O
through	through	IN	O
this	this	DT	O
residue	residue	NN	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
HMKs	HMKs	NNP	O
5	5	CD	O
and	and	CC	O
14	14	CD	O
irreversibly	irreversibly	RB	O
inhibit	inhibit	VB	O
the	the	DT	O
human	human	JJ	O
enzyme	enzyme	NNS	O
forming	form	VBG	O
a	a	DT	O
covalent	covalent	NN	O
bond	bond	NN	O
with	with	IN	O
Cys199	cys199	CD	B
.	.	.	O

Similarly	similarly	RB	O
,	,	,	O
5	5	CD	O
and	and	CC	O
14	14	CD	O
may	may	MD	O
bind	bind	VB	O
LdGSK-3	LdGSK-3	NNP	O
in	in	IN	O
the	the	DT	O
same	same	JJ	O
way	way	NN	O
.	.	.	O

Two	two	CD	O
substrate	substrate	JJ	O
competitive	competitive	JJ	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
hGSK-3Î²	hgsk-3î²	CD	O
,	,	,	O
3	3	CD	O
and	and	CC	O
4	4	CD	O
,	,	,	O
belonging	belong	VBG	O
to	to	IN	O
the	the	DT	O
ITDZ	ITDZ	NNP	O
family	family	NN	B
,	,	,	O
were	be	VBD	O
also	also	RB	O
active	active	JJ	O
against	against	IN	O
LdGSK-3	LdGSK-3	NNP	O
.	.	.	O

The	the	DT	O
substrate	substrate	NN	O
binding	bind	VBG	O
pocket	pocket	NN	O
of	of	IN	O
the	the	DT	O
enzymes	enzyme	NNS	O
is	be	VBZ	O
quite	quite	RB	O
conserved	conserve	VBN	O
respect	respect	NN	O
to	to	IN	O
the	the	DT	O
human	human	JJ	O
one	one	NN	O
,	,	,	O
so	so	CC	O
it	-PRON-	PRP	O
is	be	VBZ	O
inferred	infer	VBN	O
that	that	IN	O
the	the	DT	O
ITDZs	ITDZs	NNPS	O
were	be	VBD	O
substrate	substrate	NN	O
-	-	HYPH	O
competitive	competitive	JJ	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
the	the	DT	O
Leishmania	Leishmania	NNP	O
enzyme	enzyme	NNS	O
.	.	.	O

Remarkably	remarkably	RB	O
,	,	,	O
the	the	DT	O
two	two	CD	O
ITDZs	ITDZs	NNP	O
3	3	CD	O
and	and	CC	O
4	4	CD	O
inhibited	inhibited	JJ	O
LdGSK-3	LdGSK-3	NNP	O
at	at	IN	O
submicromolar	submicromolar	JJ	O
concentrations	concentration	NNS	O
,	,	,	O
but	but	CC	O
were	be	VBD	O
devoid	devoid	JJ	O
of	of	IN	O
significant	significant	JJ	O
leishmanicidal	leishmanicidal	JJ	O
activities	activity	NNS	O
,	,	,	O
even	even	RB	O
at	at	IN	O
the	the	DT	O
highest	high	JJS	O
concentration	concentration	NN	O
tested	test	VBN	O
50âÂµM	50âÂµM	NNP	O
.	.	.	O

Likely	likely	RB	O
they	-PRON-	PRP	O
were	be	VBD	O
unable	unable	JJ	O
to	to	TO	O
build	build	VB	O
-	-	HYPH	O
up	up	RP	O
an	an	DT	O
intracellular	intracellular	JJ	O
inhibitory	inhibitory	JJ	O
concentration	concentration	NN	O
on	on	IN	O
the	the	DT	O
parasite	parasite	NN	O
,	,	,	O
hence	hence	RB	O
a	a	DT	O
strategy	strategy	NN	O
of	of	IN	O
conjugation	conjugation	NN	O
with	with	IN	O
cell	cell	NN	O
penetrating	penetrating	NN	O
peptide	peptide	NN	O
-	-	HYPH	O
based	base	VBN	O
is	be	VBZ	O
currently	currently	RB	O
being	be	VBG	O
pursued	pursue	VBN	O
to	to	TO	O
overcome	overcome	VB	O
this	this	DT	O
drawback	drawback	NN	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
improve	improve	VB	O
the	the	DT	O
permeability	permeability	NN	O
of	of	IN	O
ITDZs	ITDZs	NNP	B
.	.	.	O

To	to	TO	O
account	account	VB	O
for	for	IN	O
the	the	DT	O
experimental	experimental	JJ	O
results	result	NNS	O
of	of	IN	O
the	the	DT	O
tested	test	VBN	O
compounds	compound	NNS	O
and	and	CC	O
to	to	TO	O
confirm	confirm	VB	O
the	the	DT	O
hypothesis	hypothesis	NN	O
described	describe	VBN	O
above	above	IN	O
,	,	,	O
molecular	molecular	JJ	O
docking	docking	NN	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
and	and	CC	O
compared	compare	VBN	O
with	with	IN	O
its	-PRON-	PRP$	O
human	human	JJ	O
counterpart	counterpart	NN	O
.	.	.	O

The	the	DT	O
computational	computational	JJ	O
studies	study	NNS	O
were	be	VBD	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
crystal	crystal	NN	O
structure	structure	NN	O
of	of	IN	O
LmjGSK-3	lmjgsk-3	JJ	B
.	.	.	O

However	however	RB	O
,	,	,	O
as	as	IN	O
the	the	DT	O
crystal	crystal	NN	O
structure	structure	NN	O
of	of	IN	O
the	the	DT	O
protein	protein	NN	O
lacks	lack	VBZ	O
a	a	DT	O
decapeptide	decapeptide	NN	O
loop	loop	NN	O
at	at	IN	O
the	the	DT	O
upper	upper	JJ	O
part	part	NN	O
of	of	IN	O
the	the	DT	O
ATP	ATP	NNP	O
binding	bind	VBG	O
pocket	pocket	NN	O
,	,	,	O
its	-PRON-	PRP$	O
sequence	sequence	NN	O
was	be	VBD	O
modelled	model	VBN	O
using	use	VBG	O
the	the	DT	O
Modeller	Modeller	NNP	O
programme	programme	NN	O
before	before	IN	O
the	the	DT	O
onset	onset	NN	O
of	of	IN	O
the	the	DT	O
analysis	analysis	NN	B
.	.	.	O

Once	once	IN	O
the	the	DT	O
protein	protein	NN	O
structure	structure	NN	O
was	be	VBD	O
completed	complete	VBN	O
,	,	,	O
a	a	DT	O
minimisation	minimisation	NN	O
step	step	NN	O
was	be	VBD	O
further	further	RB	O
performed	perform	VBN	O
.	.	.	O

As	as	IN	O
the	the	DT	O
crystal	crystal	NN	O
structure	structure	NN	O
was	be	VBD	O
in	in	IN	O
an	an	DT	O
apo	apo	NN	O
form	form	NN	O
,	,	,	O
the	the	DT	O
holo	holo	NN	O
structure	structure	NN	O
was	be	VBD	O
mimicked	mimic	VBN	O
by	by	IN	O
induced	induce	VBN	O
fit	fit	JJ	O
docking	docking	NN	O
.	.	.	O

Compound	Compound	NNP	O
6-bromo-5-methylindirubin-3â²oxime	6-bromo-5-methylindirubin-3â²oxime	CD	O
,	,	,	O
one	one	CD	O
of	of	IN	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
ATP	atp	NN	O
-	-	HYPH	O
competitive	competitive	JJ	O
inhibitor	inhibitor	NN	O
for	for	IN	O
this	this	DT	O
enzyme	enzyme	NNS	B
,	,	,	O
was	be	VBD	O
selected	select	VBN	O
for	for	IN	O
this	this	DT	O
optimisation	optimisation	NN	O
step	step	NN	O
.	.	.	O

Regarding	regard	VBG	O
TDZD	TDZD	NNP	O
,	,	,	O
ITDZ	ITDZ	NNP	O
and	and	CC	O
HMK	HMK	NNP	O
families	family	NNS	O
,	,	,	O
blind	blind	JJ	O
docking	docking	NN	O
studies	study	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
with	with	IN	O
compounds	compound	NNS	O
2	2	CD	O
,	,	,	O
4	4	CD	O
,	,	,	O
and	and	CC	O
5	5	CD	O
as	as	IN	O
representatives	representative	NNS	O
of	of	IN	O
the	the	DT	O
families	family	NNS	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
of	of	IN	O
the	the	DT	O
blind	blind	JJ	O
docking	docking	NN	O
agreed	agree	VBD	O
with	with	IN	O
our	-PRON-	PRP$	O
hypothesis	hypothesis	NN	O
;	;	:	O
TDZD	TDZD	NNP	O
2	2	CD	O
and	and	CC	O
HMKs	hmk	NNS	O
5	5	CD	O
poses	pose	NNS	O
are	be	VBP	O
allocated	allocate	VBN	O
at	at	IN	O
the	the	DT	O
entrance	entrance	NN	O
of	of	IN	O
the	the	DT	O
ATP	ATP	NNP	O
binding	bind	VBG	O
site	site	NN	O
,	,	,	O
while	while	IN	O
for	for	IN	O
ITDZ	ITDZ	NNP	O
4	4	CD	O
all	all	PDT	O
the	the	DT	O
poses	pose	NNS	O
of	of	IN	O
a	a	DT	O
predominant	predominant	JJ	O
cluster	cluster	NN	O
supported	support	VBD	O
its	-PRON-	PRP$	O
binding	binding	NN	O
in	in	IN	O
the	the	DT	O
substrate	substrate	JJ	O
pocket	pocket	NN	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
in	in	IN	O
every	every	DT	O
case	case	NN	O
the	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
for	for	IN	O
each	each	DT	O
of	of	IN	O
the	the	DT	O
families	family	NNS	O
was	be	VBD	O
confirmed	confirm	VBN	O
,	,	,	O
as	as	IN	O
illustrated	illustrate	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
1	1	CD	O
.	.	.	O

Based	base	VBN	O
on	on	IN	O
these	these	DT	O
results	result	NNS	O
,	,	,	O
a	a	DT	O
more	more	RBR	O
detailed	detailed	JJ	O
study	study	NN	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
using	use	VBG	O
additional	additional	JJ	O
regular	regular	JJ	O
docking	docking	NN	O
study	study	NN	O
.	.	.	O

For	for	IN	O
this	this	DT	O
,	,	,	O
compounds	compound	VBZ	O
2	2	CD	O
and	and	CC	O
5	5	CD	O
were	be	VBD	O
selected	select	VBN	O
as	as	IN	O
representative	representative	JJ	O
compounds	compound	NNS	O
for	for	IN	O
TDZDs	tdzd	NNS	O
and	and	CC	O
HMKs	hmk	NNS	O
chemical	chemical	NN	O
families	family	NNS	O
,	,	,	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
4	4	CD	O
.	.	.	O

This	this	DT	O
docking	docking	NN	O
study	study	NN	O
was	be	VBD	O
focussed	focusse	VBN	O
on	on	IN	O
their	-PRON-	PRP$	O
previous	previous	JJ	O
predicted	predict	VBN	O
binding	bind	VBG	O
sites	site	NNS	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
confirmed	confirm	VBD	O
a	a	DT	O
similar	similar	JJ	O
binding	binding	JJ	O
mode	mode	NN	O
of	of	IN	O
the	the	DT	O
two	two	CD	O
ITDZ	ITDZ	NNP	O
derivatives	derivative	NNS	O
inside	inside	IN	O
the	the	DT	O
substrate	substrate	NN	O
binding	bind	VBG	O
pocket	pocket	NN	O
Figure	Figure	NNP	O
1	1	CD	O
.	.	.	O

An	an	DT	O
important	important	JJ	O
number	number	NN	O
of	of	IN	O
the	the	DT	O
poses	pose	NNS	O
of	of	IN	O
TDZs	tdz	NNS	O
and	and	CC	O
HMK	HMK	NNP	O
provided	provide	VBD	O
3â4âÃ	3â4âã	CD	O
distances	distance	NNS	O
between	between	IN	O
the	the	DT	O
reactive	reactive	JJ	O
atoms	atom	NNS	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
and	and	CC	O
the	the	DT	O
Cys169	Cys169	NNS	O
of	of	IN	O
GSK-3	GSK-3	NNP	O
compatible	compatible	JJ	O
with	with	IN	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
covalent	covalent	NN	O
bond	bond	NN	O
.	.	.	O

In	in	IN	O
order	order	NN	O
to	to	TO	O
validate	validate	VB	O
this	this	DT	O
hypothesis	hypothesis	NN	O
,	,	,	O
covalent	covalent	NN	O
docking	docking	NN	O
for	for	IN	O
TDZDs	TDZDs	NNP	O
and	and	CC	O
HMK	HMK	NNP	O
5	5	CD	O
was	be	VBD	O
performed	perform	VBN	O
.	.	.	O

Distances	distance	NNS	O
between	between	IN	O
1.5â2.5âÃ	1.5â2.5âã	CD	O
were	be	VBD	O
obtained	obtain	VBN	O
in	in	IN	O
most	most	JJS	O
of	of	IN	O
the	the	DT	O
poses	pose	NNS	O
for	for	IN	O
compounds	compound	NNS	O
1	1	CD	O
,	,	,	O
2	2	CD	O
and	and	CC	O
5	5	CD	O
,	,	,	O
typical	typical	JJ	O
of	of	IN	O
a	a	DT	O
covalent	covalent	NN	O
bond	bond	NN	O
Figures	figure	NNS	O
1	1	CD	O
.	.	.	O

In	in	IN	O
all	all	DT	O
,	,	,	O
the	the	DT	O
data	datum	NNS	O
purported	purport	VBD	O
a	a	DT	O
covalent	covalent	NN	O
inhibition	inhibition	NN	O
of	of	IN	O
the	the	DT	O
enzyme	enzyme	NNS	O
for	for	IN	O
the	the	DT	O
three	three	CD	O
compounds	compound	NNS	O
.	.	.	O

Binding	bind	VBG	O
mode	mode	NN	O
into	into	IN	O
the	the	DT	O
LmjGSK-3	LmjGSK-3	NNP	O
enzyme	enzyme	NNS	O
for	for	IN	O
ITDZ	ITDZ	NNP	O
,	,	,	O
TDZD	TDZD	NNP	O
,	,	,	O
and	and	CC	O
HMK	HMK	NNP	O
representative	representative	JJ	O
compounds	compound	NNS	O
.	.	.	O

Blind	blind	JJ	O
docking	docking	NN	O
poses	pose	NNS	O
obtained	obtain	VBN	O
from	from	IN	O
the	the	DT	O
most	most	RBS	O
representative	representative	JJ	O
clusters	cluster	NNS	O
for	for	IN	O
2	2	CD	O
and	and	CC	O
4	4	CD	O
in	in	IN	O
the	the	DT	O
ATP	ATP	NNP	O
binding	bind	VBG	O
site	site	NN	O
and	and	CC	O
the	the	DT	O
substrate	substrate	NN	O
binding	binding	NN	O
site	site	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Superimposition	superimposition	NN	O
of	of	IN	O
most	most	JJS	O
representative	representative	JJ	O
regular	regular	JJ	O
docking	docking	NN	O
results	result	NNS	O
of	of	IN	O
ITDZ	ITDZ	NNP	O
compounds	compound	NNS	O
3	3	CD	O
and	and	CC	O
4	4	CD	O
.	.	.	O

Superimposition	superimposition	NN	O
of	of	IN	O
the	the	DT	O
best	good	JJS	O
covalent	covalent	NN	O
docking	docking	NN	O
poses	pose	NNS	O
obtained	obtain	VBN	O
for	for	IN	O
TDZDs	TDZDs	NNP	O
and	and	CC	O
HMK	HMK	NNP	O
5	5	CD	O
.	.	.	O

Detailed	detailed	JJ	O
view	view	NN	O
of	of	IN	O
the	the	DT	O
covalent	covalent	NN	O
docking	docking	NN	O
for	for	IN	O
compound	compound	NN	O
2	2	CD	O
.	.	.	O

Compounds	compound	NNS	O
13	13	CD	O
and	and	CC	O
14	14	CD	O
are	be	VBP	O
maleimide	maleimide	NN	O
derivatives	derivative	NNS	O
with	with	IN	O
a	a	DT	O
high	high	JJ	O
degree	degree	NN	O
of	of	IN	O
chemical	chemical	NN	O
similarity	similarity	NN	O
,	,	,	O
but	but	CC	O
with	with	IN	O
different	different	JJ	O
binding	binding	NN	O
modes	mode	NNS	O
to	to	IN	O
the	the	DT	O
human	human	JJ	O
enzyme	enzyme	NNS	O
.	.	.	O

Maleimide	Maleimide	NNP	O
13	13	CD	O
is	be	VBZ	O
a	a	DT	O
reversible	reversible	JJ	O
ATP	atp	NN	O
-	-	HYPH	O
competitive	competitive	JJ	O
inhibitor	inhibitor	NN	O
,	,	,	O
while	while	IN	O
maleimide	maleimide	NN	O
14	14	CD	O
is	be	VBZ	O
an	an	DT	O
irreversible	irreversible	JJ	O
ATP	atp	NN	O
-	-	HYPH	O
competitive	competitive	JJ	O
inhibitor	inhibitor	NN	O
of	of	IN	O
hGSK-3Î²	hgsk-3î²	CD	O
due	due	IN	O
to	to	IN	O
its	-PRON-	PRP$	O
halomethylketone	halomethylketone	NN	O
tail	tail	NN	B
.	.	.	O

Significantly	significantly	RB	O
,	,	,	O
13	13	CD	O
did	do	VBD	O
not	not	RB	O
inhibit	inhibit	VB	O
LdGSK-3	LdGSK-3	NNP	O
activity	activity	NN	O
,	,	,	O
as	as	IN	O
the	the	DT	O
compound	compound	NN	O
can	can	MD	O
not	not	RB	O
reach	reach	VB	O
the	the	DT	O
deep	deep	JJ	O
part	part	NN	O
of	of	IN	O
the	the	DT	O
ATP	ATP	NNP	O
binding	bind	VBG	O
cavity	cavity	NN	O
,	,	,	O
in	in	IN	O
agreement	agreement	NN	O
with	with	IN	O
docking	docking	NN	O
studies	study	NNS	O
Figure	figure	NN	O
2	2	CD	O
.	.	.	O

According	accord	VBG	O
to	to	IN	O
a	a	DT	O
crystal	crystal	NN	O
structure	structure	NN	O
available	available	JJ	O
for	for	IN	O
the	the	DT	O
hGSK-3	hGSK-3	NNP	B
,	,	,	O
the	the	DT	O
maleimide	maleimide	NN	O
scaffold	scaffold	JJ	O
interacts	interact	VBZ	O
with	with	IN	O
the	the	DT	O
Asp133	asp133	CD	O
through	through	IN	O
a	a	DT	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
at	at	IN	O
the	the	DT	O
deepest	deep	JJS	O
part	part	NN	O
of	of	IN	O
the	the	DT	O
ATP	ATP	NNP	O
binding	bind	VBG	O
cavity	cavity	NN	O
.	.	.	O

This	this	DT	O
Asp	Asp	NNP	O
residue	residue	NN	O
is	be	VBZ	O
replaced	replace	VBN	O
with	with	IN	O
Glu101	glu101	CD	O
at	at	IN	O
the	the	DT	O
LdGSK-3	LdGSK-3	NNP	O
.	.	.	O

This	this	DT	O
conservative	conservative	JJ	O
replacement	replacement	NN	O
did	do	VBD	O
not	not	RB	O
significantly	significantly	RB	O
modify	modify	VB	O
the	the	DT	O
structure	structure	NN	O
of	of	IN	O
the	the	DT	O
binding	bind	VBG	O
site	site	NN	O
,	,	,	O
as	as	IN	O
it	-PRON-	PRP	O
is	be	VBZ	O
the	the	DT	O
backbone	backbone	NN	O
that	that	WDT	O
is	be	VBZ	O
mostly	mostly	RB	O
responsible	responsible	JJ	O
for	for	IN	O
the	the	DT	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
and	and	CC	O
not	not	RB	O
the	the	DT	O
lateral	lateral	JJ	O
chain	chain	NN	O
that	that	WDT	O
points	point	VBZ	O
outwards	outward	VBZ	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
of	of	IN	O
the	the	DT	O
enzyme	enzyme	NNS	O
,	,	,	O
making	make	VBG	O
the	the	DT	O
number	number	NN	O
of	of	IN	O
its	-PRON-	PRP$	O
methylene	methylene	JJ	O
groups	group	NNS	O
irrelevant	irrelevant	JJ	O
for	for	IN	O
this	this	DT	O
interaction	interaction	NN	O
.	.	.	O

In	in	IN	O
contrast	contrast	NN	O
,	,	,	O
its	-PRON-	PRP$	O
adjacent	adjacent	JJ	O
Leu132	leu132	NN	O
in	in	IN	O
the	the	DT	O
human	human	JJ	O
enzyme	enzyme	NNS	O
is	be	VBZ	O
mutated	mutate	VBN	O
by	by	IN	O
the	the	DT	O
bulkier	bulkier	NN	O
Met100	Met100	NNS	O
in	in	IN	O
the	the	DT	O
Leishmania	Leishmania	NNP	O
enzyme	enzyme	NNS	O
Figure	figure	NN	O
2	2	CD	O
.	.	.	O

This	this	DT	O
change	change	NN	O
jeopardises	jeopardise	VBZ	O
the	the	DT	O
access	access	NN	O
of	of	IN	O
13	13	CD	O
into	into	IN	O
the	the	DT	O
deepest	deep	JJS	O
part	part	NN	O
of	of	IN	O
the	the	DT	O
cavity	cavity	NN	O
,	,	,	O
severely	severely	RB	O
precluding	preclude	VBG	O
the	the	DT	O
enzyme	enzyme	NNS	O
inhibition	inhibition	NN	O
.	.	.	O

On	on	IN	O
the	the	DT	O
other	other	JJ	O
hand	hand	NN	O
,	,	,	O
the	the	DT	O
inhibition	inhibition	NN	O
by	by	IN	O
the	the	DT	O
irreversible	irreversible	JJ	O
inhibitor	inhibitor	NN	O
14	14	CD	O
is	be	VBZ	O
lower	low	JJR	O
for	for	IN	O
LdGSK-3	LdGSK-3	NNP	O
respect	respect	NN	O
to	to	IN	O
the	the	DT	O
human	human	JJ	O
enzyme	enzyme	NNS	O
,	,	,	O
despite	despite	IN	O
its	-PRON-	PRP$	O
IC50	IC50	NNP	O
at	at	IN	O
low	low	JJ	O
micromolar	micromolar	JJ	O
concentrations	concentration	NNS	O
.	.	.	O

According	accord	VBG	O
to	to	IN	O
the	the	DT	O
regular	regular	JJ	O
free	free	JJ	O
docking	docking	NN	O
results	result	NNS	O
,	,	,	O
the	the	DT	O
methylene	methylene	NN	O
group	group	NN	O
attached	attach	VBD	O
to	to	IN	O
the	the	DT	O
bromine	bromine	NN	O
in	in	IN	O
14	14	CD	O
is	be	VBZ	O
oriented	orient	VBN	O
towards	towards	IN	O
the	the	DT	O
SH	SH	NNP	O
of	of	IN	O
the	the	DT	O
Cys169	Cys169	NNS	O
with	with	IN	O
a	a	DT	O
distance	distance	NN	O
of	of	IN	O
3.7âÃ	3.7âã	CD	O
		_SP	O
.	.	.	O

The	the	DT	O
orientation	orientation	NN	O
of	of	IN	O
the	the	DT	O
molecule	molecule	NN	O
and	and	CC	O
the	the	DT	O
distance	distance	NN	O
suggest	suggest	VBP	O
an	an	DT	O
irreversible	irreversible	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
the	the	DT	O
enzyme	enzyme	NNS	O
.	.	.	O

This	this	DT	O
fact	fact	NN	O
was	be	VBD	O
confirmed	confirm	VBN	O
in	in	IN	O
the	the	DT	O
covalent	covalent	NN	O
docking	docking	NN	O
,	,	,	O
showing	show	VBG	O
a	a	DT	O
distance	distance	NN	O
of	of	IN	O
1.8âÃ	1.8âã	CD	O
between	between	IN	O
the	the	DT	O
methylene	methylene	NN	O
and	and	CC	O
the	the	DT	O
sulphur	sulphur	NNP	O
,	,	,	O
typical	typical	JJ	O
of	of	IN	O
this	this	DT	O
class	class	NN	O
of	of	IN	O
bond	bond	NN	O
.	.	.	O

Superposition	superposition	NN	O
of	of	IN	O
the	the	DT	O
human	human	NN	O
and	and	CC	O
Leishmania	Leishmania	NNP	O
GSK-3	GSK-3	NNP	O
enzymes	enzyme	VBZ	O
.	.	.	O

Key	key	JJ	O
mutation	mutation	NN	O
in	in	IN	O
the	the	DT	O
ATP	ATP	NNP	O
binding	bind	VBG	O
site	site	NN	O
is	be	VBZ	O
depicted	depict	VBN	O
as	as	IN	O
sticks	stick	NNS	O
.	.	.	O

Superposition	superposition	NN	O
of	of	IN	O
the	the	DT	O
poses	pose	NNS	O
of	of	IN	O
maleimide	maleimide	NN	O
13	13	CD	O
in	in	IN	O
the	the	DT	O
human	human	NN	O
and	and	CC	O
Leishmania	Leishmania	NNP	O
GSK-3	GSK-3	NNP	O
enzymes	enzyme	VBZ	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
quinoline	quinoline	NNP	O
11	11	CD	O
,	,	,	O
an	an	DT	O
allosteric	allosteric	JJ	O
inhibitor	inhibitor	NN	O
of	of	IN	O
hGSK-3Î²	hgsk-3î²	CD	O
was	be	VBD	O
inactive	inactive	JJ	O
in	in	IN	O
LdGSK-3	LdGSK-3	NNP	O
.	.	.	O

The	the	DT	O
cation	cation	NN	O
-	-	:	O
Ï	ï	JJ	O
interaction	interaction	NN	O
of	of	IN	O
the	the	DT	O
quinoline	quinoline	NN	O
ring	ring	NN	O
with	with	IN	O
Arg209	arg209	CD	O
is	be	VBZ	O
key	key	JJ	O
in	in	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
the	the	DT	O
human	human	JJ	O
enzyme	enzyme	NNS	B
.	.	.	O

This	this	DT	O
Arg	Arg	NNP	O
is	be	VBZ	O
replaced	replace	VBN	O
with	with	IN	O
Pro178	pro178	CD	O
in	in	IN	O
LmjGSK-3	LmjGSK-3	NNP	O
.	.	.	O

The	the	DT	O
change	change	NN	O
of	of	IN	O
the	the	DT	O
cationic	cationic	JJ	O
Arg	arg	NN	O
by	by	IN	O
the	the	DT	O
neutral	neutral	JJ	O
Pro	Pro	NNP	O
not	not	RB	O
only	only	RB	O
modifies	modify	VBZ	O
the	the	DT	O
electrostatic	electrostatic	JJ	O
environment	environment	NN	O
of	of	IN	O
this	this	DT	O
pocket	pocket	NN	O
,	,	,	O
but	but	CC	O
also	also	RB	O
its	-PRON-	PRP$	O
rigidity	rigidity	NN	O
;	;	:	O
as	as	IN	O
Pro	pro	FW	O
imposed	impose	VBD	O
a	a	DT	O
strong	strong	JJ	O
conformational	conformational	JJ	O
constraint	constraint	NN	O
,	,	,	O
absent	absent	JJ	O
in	in	IN	O
the	the	DT	O
flexible	flexible	JJ	O
Arg	arg	NN	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
this	this	DT	O
single	single	JJ	O
mutation	mutation	NN	O
ruled	rule	VBD	O
out	out	RP	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
LdGSK-3	LdGSK-3	NNP	O
by	by	IN	O
11	11	CD	O
.	.	.	O

In	in	IN	O
the	the	DT	O
quest	quest	NN	O
for	for	IN	O
novel	novel	JJ	O
scaffolds	scaffold	NNS	O
of	of	IN	O
LdGSK-3	LdGSK-3	NNP	O
inhibitors	inhibitor	NNS	O
,	,	,	O
the	the	DT	O
previous	previous	JJ	O
search	search	NN	O
inside	inside	IN	O
putative	putative	JJ	O
collections	collection	NNS	O
of	of	IN	O
GSK-3	GSK-3	NNP	O
inhibitors	inhibitor	NNS	O
was	be	VBD	O
complemented	complement	VBN	O
with	with	IN	O
an	an	DT	O
inverse	inverse	NN	O
strategy	strategy	NN	O
,	,	,	O
the	the	DT	O
search	search	NN	O
for	for	IN	O
LdGSK-3	LdGSK-3	NNP	O
inhibitors	inhibitor	NNS	O
inside	inside	IN	O
the	the	DT	O
186	186	CD	O
compounds	compound	NNS	O
belonging	belong	VBG	O
to	to	IN	O
the	the	DT	O
Leishbox	Leishbox	NNP	O
collection	collection	NN	B
.	.	.	O

All	all	PDT	O
the	the	DT	O
kinetoboxes	kinetoboxe	NNS	O
,	,	,	O
including	include	VBG	O
Leishbox	Leishbox	NNP	O
,	,	,	O
were	be	VBD	O
selected	select	VBN	O
from	from	IN	O
unbiased	unbiased	JJ	O
phenotypic	phenotypic	NN	O
screening	screening	NN	O
.	.	.	O

Further	further	JJ	O
studies	study	NNS	O
have	have	VBP	O
been	be	VBN	O
reported	report	VBN	O
recently	recently	RB	O
using	use	VBG	O
kinetoboxes	kinetoboxe	NNS	O
,	,	,	O
aimed	aim	VBN	O
at	at	IN	O
expanding	expand	VBG	O
the	the	DT	O
pharmacological	pharmacological	JJ	O
potential	potential	NN	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	B
.	.	.	O

However	however	RB	O
,	,	,	O
studies	study	NNS	O
focussed	focusse	VBN	O
on	on	IN	O
the	the	DT	O
experimental	experimental	JJ	O
identification	identification	NN	O
of	of	IN	O
the	the	DT	O
mechanism	mechanism	NN	O
of	of	IN	O
action	action	NN	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	O
are	be	VBP	O
still	still	RB	O
scarce	scarce	JJ	B
.	.	.	O

The	the	DT	O
compounds	compound	NNS	O
25â210	25â210	CD	O
were	be	VBD	O
assayed	assay	VBN	O
at	at	IN	O
10âÂµM	10ââµm	CD	O
for	for	IN	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
LdGSK-3	LdGSK-3	NNP	O
inhibition	inhibition	NN	O
.	.	.	O

Nine	nine	CD	O
molecules	molecule	NNS	O
showed	show	VBD	O
a	a	DT	O
percentage	percentage	NN	O
of	of	IN	O
inhibition	inhibition	NN	O
higher	high	JJR	O
than	than	IN	O
50	50	CD	O
%	%	NN	O
being	be	VBG	O
selected	select	VBN	O
for	for	IN	O
subsequent	subsequent	JJ	O
IC50	IC50	NNP	O
calculation	calculation	NN	O
.	.	.	O

Despite	despite	IN	O
repetitive	repetitive	JJ	O
experiments	experiment	NNS	O
,	,	,	O
only	only	RB	O
seven	seven	CD	O
resulted	result	VBD	O
with	with	IN	O
a	a	DT	O
reliable	reliable	JJ	O
IC50	IC50	NNP	O
inside	inside	IN	O
the	the	DT	O
submicromolar	submicromolar	JJ	O
or	or	CC	O
low	low	JJ	O
micromolar	micromolar	JJ	O
ranges	range	NNS	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
the	the	DT	O
selectivity	selectivity	NN	O
of	of	IN	O
these	these	DT	O
hits	hit	NNS	O
was	be	VBD	O
assessed	assess	VBN	O
by	by	IN	O
hGSK-3Î²	hgsk-3î²	CD	O
inhibition	inhibition	NN	O
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
for	for	IN	O
both	both	DT	O
enzymes	enzyme	NNS	O
were	be	VBD	O
quite	quite	RB	O
similar	similar	JJ	O
most	most	RBS	O
likely	likely	RB	O
due	due	IN	O
to	to	IN	O
their	-PRON-	PRP$	O
binding	binding	NN	O
into	into	IN	O
the	the	DT	O
highly	highly	RB	O
preserved	preserve	VBN	O
ATP	atp	NN	O
binding	bind	VBG	O
site	site	NN	O
of	of	IN	O
the	the	DT	O
enzymes	enzyme	NNS	O
.	.	.	O

Consequently	consequently	RB	O
,	,	,	O
the	the	DT	O
discrimination	discrimination	NN	O
between	between	IN	O
human	human	JJ	O
and	and	CC	O
leishmanial	leishmanial	JJ	O
GSK-3	GSK-3	NNP	O
was	be	VBD	O
rather	rather	RB	O
poor	poor	JJ	O
.	.	.	O

Indirubin-3â-monoxime-5-sulphonic	indirubin-3â-monoxime-5-sulphonic	JJ	O
acid	acid	NN	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
reference	reference	NN	O
of	of	IN	O
the	the	DT	O
assay	assay	NN	O
:	:	:	O
IC50	ic50	NN	O
=	=	SYM	O
2.4âÂ±â0.2âÎ¼M.	2.4ââ±â0.2âî¼m.	CD	O
N	n	CD	O
--	--	:	O
Nâ²-urea	Nâ²-urea	NNP	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
reference	reference	NN	O
of	of	IN	O
the	the	DT	O
assay	assay	NN	O
:	:	:	O
IC50	ic50	NN	O
=	=	SYM	O
0.10âÂ±â0.03âÎ¼M.	0.10ââ±â0.03âî¼m.	CD	O
Standard	standard	JJ	O
deviation	deviation	NN	O
not	not	RB	O
calculated	calculate	VBN	O
due	due	IN	O
to	to	IN	O
experimental	experimental	JJ	O
issues	issue	NNS	O
.	.	.	O

The	the	DT	O
chemical	chemical	NN	O
structures	structure	NNS	O
of	of	IN	O
these	these	DT	O
7	7	CD	O
compounds	compound	NNS	O
belong	belong	VBP	O
to	to	IN	O
three	three	CD	O
different	different	JJ	O
chemical	chemical	NN	O
families	family	NNS	O
:	:	:	O
benzoimidazole	benzoimidazole	NNP	O
,	,	,	O
N	N	NNP	O
-	-	HYPH	O
phenylpyrimidine-2-amine	phenylpyrimidine-2-amine	NNP	O
and	and	CC	O
oxadiazole	oxadiazole	RB	O
.	.	.	O

Some	some	DT	O
initial	initial	JJ	O
structural	structural	JJ	O
insights	insight	NNS	O
can	can	MD	O
be	be	VB	O
established	establish	VBN	O
from	from	IN	O
the	the	DT	O
active	active	JJ	O
and	and	CC	O
inactive	inactive	JJ	O
members	member	NNS	O
of	of	IN	O
these	these	DT	O
three	three	CD	O
families	family	NNS	O
,	,	,	O
compiled	compile	VBN	O
in	in	IN	O
Table	table	NN	O
S3âS5	s3âs5	NN	O
.	.	.	O

For	for	IN	O
N	N	NNP	O
-	-	HYPH	O
phenylpyrimidine-2-amines	phenylpyrimidine-2-amines	NNPS	O
,	,	,	O
active	active	JJ	O
compounds	compound	NNS	O
lack	lack	NN	O
substitution	substitution	NN	O
at	at	IN	O
5	5	CD	O
and	and	CC	O
6	6	CD	O
position	position	NN	O
and	and	CC	O
showed	show	VBD	O
an	an	DT	O
aromatic	aromatic	JJ	O
substituent	substituent	NN	O
in	in	IN	O
position	position	NN	O
3	3	CD	O
,	,	,	O
together	together	RB	O
with	with	IN	O
a	a	DT	O
free	free	JJ	O
amino	amino	NN	O
group	group	NN	O
.	.	.	O

With	with	IN	O
regard	regard	NN	O
to	to	IN	O
benzoimidazole	benzoimidazole	NNP	O
scaffold	scaffold	NNP	O
,	,	,	O
only	only	RB	O
the	the	DT	O
two	two	CD	O
derivatives	derivative	NNS	O
with	with	IN	O
a	a	DT	O
5-phenylpyridin-2-amine	5-phenylpyridin-2-amine	NNS	O
are	be	VBP	O
active	active	JJ	O
,	,	,	O
highlighting	highlight	VBG	O
to	to	IN	O
the	the	DT	O
importance	importance	NN	O
of	of	IN	O
this	this	DT	O
substituent	substituent	NN	O
to	to	TO	O
inhibit	inhibit	VB	O
GSK-3	GSK-3	NNP	O
.	.	.	O

Only	only	RB	O
a	a	DT	O
single	single	JJ	O
oxadiazole	oxadiazole	NN	O
showed	show	VBD	O
a	a	DT	O
significant	significant	JJ	O
inhibition	inhibition	NN	O
against	against	IN	O
LdGSK-3	LdGSK-3	NNP	O
;	;	:	O
this	this	DT	O
fact	fact	NN	O
,	,	,	O
together	together	RB	O
with	with	IN	O
the	the	DT	O
poor	poor	JJ	O
representation	representation	NN	O
of	of	IN	O
this	this	DT	O
scaffold	scaffold	NN	O
in	in	IN	O
the	the	DT	O
Leishbox	Leishbox	NNP	O
,	,	,	O
precluded	preclude	VBD	O
the	the	DT	O
establishment	establishment	NN	O
of	of	IN	O
a	a	DT	O
reliable	reliable	JJ	O
structure	structure	NN	O
-	-	HYPH	O
activity	activity	NN	O
relationship	relationship	NN	O
.	.	.	O

Consequently	consequently	RB	O
,	,	,	O
we	-PRON-	PRP	O
focussed	focusse	VBD	O
on	on	IN	O
the	the	DT	O
other	other	JJ	O
two	two	CD	O
families	family	NNS	O
.	.	.	O

Molecular	molecular	JJ	O
modelling	modelling	NN	O
studies	study	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
with	with	IN	O
N	N	NNP	O
-	-	HYPH	O
phenylpyrimidine-2-amines	phenylpyrimidine-2-amines	NNPS	O
and	and	CC	O
benzoimidazoles	benzoimidazole	NNS	O
to	to	TO	O
infer	infer	VB	O
their	-PRON-	PRP$	O
mode	mode	NN	O
of	of	IN	O
binding	bind	VBG	O
and	and	CC	O
their	-PRON-	PRP$	O
mechanism	mechanism	NN	O
of	of	IN	O
action	action	NN	O
.	.	.	O

In	in	IN	O
a	a	DT	O
first	first	JJ	O
step	step	NN	O
,	,	,	O
an	an	DT	O
unbiased	unbiased	JJ	O
blind	blind	JJ	O
docking	docking	NN	O
was	be	VBD	O
performed	perform	VBN	O
for	for	IN	O
one	one	CD	O
member	member	NN	O
of	of	IN	O
each	each	DT	O
family	family	NN	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
identify	identify	VB	O
the	the	DT	O
most	most	RBS	O
likely	likely	JJ	O
region	region	NN	O
of	of	IN	O
LmjGSK-3	LmjGSK-3	NNP	O
that	that	WDT	O
interacts	interact	VBZ	O
with	with	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
.	.	.	O

As	as	IN	O
suspected	suspect	VBN	O
by	by	IN	O
their	-PRON-	PRP$	O
similar	similar	JJ	O
IC50	IC50	NNP	O
values	value	NNS	O
for	for	IN	O
Leishmania	Leishmania	NNP	O
and	and	CC	O
human	human	JJ	O
GSK-3	GSK-3	NNP	O
,	,	,	O
both	both	DT	O
chemical	chemical	NN	O
families	family	NNS	O
interact	interact	VBP	O
with	with	IN	O
the	the	DT	O
ATP	atp	NN	O
binding	bind	VBG	O
site	site	NN	O
.	.	.	O

Once	once	IN	O
the	the	DT	O
theoretical	theoretical	JJ	O
binding	binding	NN	O
site	site	NN	O
was	be	VBD	O
identified	identify	VBN	O
,	,	,	O
induced	induce	VBD	O
fit	fit	JJ	O
docking	docking	NN	O
studies	study	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
with	with	IN	O
one	one	CD	O
of	of	IN	O
the	the	DT	O
most	most	RBS	O
active	active	JJ	O
compounds	compound	NNS	O
,	,	,	O
the	the	DT	O
pyrimidine	pyrimidine	NN	O
95	95	CD	O
IC50	IC50	NNP	O
=	=	SYM	O
0.46âÂµM	0.46âÂµM	NNP	O
,	,	,	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
optimise	optimise	VB	O
the	the	DT	O
interaction	interaction	NN	O
of	of	IN	O
the	the	DT	O
residues	residue	NNS	O
involved	involve	VBN	O
in	in	IN	O
the	the	DT	O
binding	binding	NN	O
of	of	IN	O
this	this	DT	O
inhibitor	inhibitor	NN	O
.	.	.	O

The	the	DT	O
rationale	rationale	NN	O
underlying	underlie	VBG	O
this	this	DT	O
step	step	NN	O
is	be	VBZ	O
the	the	DT	O
readjustment	readjustment	NN	O
of	of	IN	O
the	the	DT	O
protein	protein	NN	O
from	from	IN	O
its	-PRON-	PRP$	O
apo	apo	NNP	O
form	form	NN	O
into	into	IN	O
a	a	DT	O
holo	holo	NN	O
state	state	NN	O
.	.	.	O

Induced	induce	VBN	O
fit	fit	JJ	O
docking	docking	NN	O
defined	define	VBD	O
a	a	DT	O
key	key	JJ	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
between	between	IN	O
Glu101	glu101	CD	O
and	and	CC	O
the	the	DT	O
amino	amino	JJ	O
group	group	NN	O
from	from	IN	O
the	the	DT	O
indazole	indazole	JJ	O
moiety	moiety	NN	O
of	of	IN	O
compound	compound	NNP	O
95	95	CD	O
.	.	.	O

Additionally	additionally	RB	O
,	,	,	O
the	the	DT	O
sulphone	sulphone	NN	O
group	group	NN	O
was	be	VBD	O
able	able	JJ	O
to	to	TO	O
establish	establish	VB	O
a	a	DT	O
double	double	JJ	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
with	with	IN	O
both	both	CC	O
Phe31	Phe31	NNP	O
and	and	CC	O
Lys49	Lys49	NNP	O
,	,	,	O
being	be	VBG	O
the	the	DT	O
latter	latter	JJ	O
a	a	DT	O
catalytic	catalytic	JJ	O
residue	residue	NN	O
of	of	IN	O
the	the	DT	O
protein	protein	NN	O
.	.	.	O

Proposed	propose	VBN	O
binding	bind	VBG	O
mode	mode	NN	O
for	for	IN	O
compound	compound	NN	O
95	95	CD	O
with	with	IN	O
LmjGSK-3	LmjGSK-3	NNP	O
with	with	IN	O
the	the	DT	O
modelled	modelled	JJ	O
decapeptide	decapeptide	NNP	O
loop	loop	NN	O
.	.	.	O

Zoom	Zoom	NNP	O
of	of	IN	O
ATP	ATP	NNP	O
binding	bind	VBG	O
pocket	pocket	NN	O
showed	show	VBD	O
the	the	DT	O
most	most	RBS	O
relevant	relevant	JJ	O
interactions	interaction	NNS	O
of	of	IN	O
95	95	CD	O
with	with	IN	O
nearby	nearby	JJ	O
residues	residue	NNS	O
of	of	IN	O
the	the	DT	O
binding	bind	VBG	O
site	site	NN	O
.	.	.	O

Afterwards	afterwards	RB	O
,	,	,	O
the	the	DT	O
docking	docking	NN	O
of	of	IN	O
the	the	DT	O
other	other	JJ	O
N	N	NNP	O
-	-	HYPH	O
phenylpyrimidine-2-amine	phenylpyrimidine-2-amine	NNP	O
derivatives	derivative	NNS	O
119	119	CD	O
,	,	,	O
124	124	CD	O
and	and	CC	O
128	128	CD	O
,	,	,	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
using	use	VBG	O
Autodock	Autodock	NNP	O
.	.	.	O

These	these	DT	O
three	three	CD	O
compounds	compound	NNS	O
maintained	maintain	VBD	O
the	the	DT	O
key	key	JJ	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
of	of	IN	O
their	-PRON-	PRP$	O
indazole	indazole	NN	O
group	group	NN	O
with	with	IN	O
Glu101	glu101	CD	O
,	,	,	O
as	as	IN	O
described	describe	VBN	O
for	for	IN	O
95	95	CD	O
.	.	.	O

The	the	DT	O
merging	merging	NN	O
of	of	IN	O
the	the	DT	O
most	most	RBS	O
representative	representative	JJ	O
docking	docking	NN	O
poses	pose	NNS	O
for	for	IN	O
the	the	DT	O
different	different	JJ	O
N	N	NNP	O
-	-	HYPH	O
phenylpyrimidine-2-amines	phenylpyrimidine-2-amines	NNP	O
is	be	VBZ	O
represented	represent	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
4	4	CD	O
.	.	.	O

The	the	DT	O
detailed	detailed	JJ	O
analysis	analysis	NN	O
of	of	IN	O
the	the	DT	O
resulting	result	VBG	O
poses	pose	NNS	O
disclosed	disclose	VBD	O
a	a	DT	O
similar	similar	JJ	O
binding	binding	JJ	O
mode	mode	NN	O
for	for	IN	O
95	95	CD	O
and	and	CC	O
124	124	CD	O
,	,	,	O
in	in	IN	O
agreement	agreement	NN	O
with	with	IN	O
their	-PRON-	PRP$	O
similar	similar	JJ	O
structures	structure	NNS	O
.	.	.	O

The	the	DT	O
primary	primary	JJ	O
amine	amine	NN	O
of	of	IN	O
the	the	DT	O
thiazole	thiazole	NN	O
ring	ring	NN	O
formed	form	VBD	O
a	a	DT	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
with	with	IN	O
Glu101	glu101	CD	O
,	,	,	O
while	while	IN	O
the	the	DT	O
sulphone	sulphone	NN	O
group	group	NN	O
preserves	preserve	VBZ	O
its	-PRON-	PRP$	O
double	double	JJ	O
interaction	interaction	NN	O
with	with	IN	O
Phe31	Phe31	NNP	O
and	and	CC	O
Lys49	Lys49	NNP	O
,	,	,	O
as	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
4	4	CD	O
.	.	.	O

For	for	IN	O
119	119	CD	O
,	,	,	O
an	an	DT	O
ionic	ionic	JJ	O
interaction	interaction	NN	O
at	at	IN	O
physiological	physiological	JJ	O
pH	pH	NNP	O
was	be	VBD	O
established	establish	VBN	O
between	between	IN	O
the	the	DT	O
cationic	cationic	JJ	O
tertiary	tertiary	JJ	O
amine	amine	NN	O
and	and	CC	O
the	the	DT	O
anionic	anionic	NNP	O
carboxylic	carboxylic	JJ	O
group	group	NN	O
of	of	IN	O
the	the	DT	O
side	side	NN	O
chain	chain	NN	O
of	of	IN	O
Glu101	glu101	CD	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
the	the	DT	O
primary	primary	JJ	O
amine	amine	NN	O
group	group	NN	O
at	at	IN	O
the	the	DT	O
other	other	JJ	O
side	side	NN	O
of	of	IN	O
the	the	DT	O
molecule	molecule	NN	O
formed	form	VBD	O
a	a	DT	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
with	with	IN	O
Asp170	asp170	CD	O
Figure	figure	NN	O
4	4	CD	O
.	.	.	O

The	the	DT	O
same	same	JJ	O
interactions	interaction	NNS	O
for	for	IN	O
128	128	CD	O
inside	inside	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
of	of	IN	O
LmjGSK-3	LmjGSK-3	NNP	O
were	be	VBD	O
surmised	surmise	VBN	O
due	due	IN	O
to	to	IN	O
its	-PRON-	PRP$	O
chemical	chemical	NN	O
similarity	similarity	NN	O
with	with	IN	O
119	119	CD	O
.	.	.	O

Docking	docking	NN	O
results	result	NNS	O
for	for	IN	O
the	the	DT	O
N	N	NNP	O
-	-	HYPH	O
phenylpyrimidine-2-amines	phenylpyrimidine-2-amines	NNP	O
into	into	IN	O
modelled	model	VBN	O
LmjGSK-3	LmjGSK-3	NNP	O
.	.	.	O

Superposition	superposition	NN	O
of	of	IN	O
compounds	compound	NNS	O
124	124	CD	O
,	,	,	O
119	119	CD	O
and	and	CC	O
95	95	CD	O
on	on	IN	O
LmjGSK-3	LmjGSK-3	NNP	O
protein	protein	NN	O
.	.	.	O

Key	key	JJ	O
residues	residue	NNS	O
were	be	VBD	O
labelled	label	VBN	O
.	.	.	O

Binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
compound	compound	NN	O
124	124	CD	O
.	.	.	O

The	the	DT	O
main	main	JJ	O
interactions	interaction	NNS	O
were	be	VBD	O
highlighted	highlight	VBN	O
.	.	.	O

Binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
compound	compound	NN	O
119	119	CD	O
showing	show	VBG	O
the	the	DT	O
main	main	JJ	O
interactions	interaction	NNS	O
found	find	VBN	O
in	in	IN	O
the	the	DT	O
complex	complex	NN	O
.	.	.	O

Concerning	concern	VBG	O
the	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
71	71	CD	O
,	,	,	O
as	as	IN	O
representative	representative	NN	O
of	of	IN	O
the	the	DT	O
benzoimidazole	benzoimidazole	NNP	O
family	family	NN	O
,	,	,	O
its	-PRON-	PRP$	O
sulphone	sulphone	NN	O
group	group	NN	O
formed	form	VBD	O
a	a	DT	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
with	with	IN	O
Phe31	Phe31	NNP	O
,	,	,	O
while	while	IN	O
two	two	CD	O
additional	additional	JJ	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
were	be	VBD	O
formed	form	VBN	O
between	between	IN	O
the	the	DT	O
primary	primary	JJ	O
amine	amine	NN	O
with	with	IN	O
Asp170	asp170	CD	O
and	and	CC	O
the	the	DT	O
secondary	secondary	JJ	O
amine	amine	NN	O
from	from	IN	O
the	the	DT	O
benzoimidazole	benzoimidazole	NNP	O
moiety	moiety	NN	O
with	with	IN	O
Ala26	Ala26	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

A	a	DT	O
similar	similar	JJ	O
pattern	pattern	NN	O
of	of	IN	O
interactions	interaction	NNS	O
was	be	VBD	O
inferred	infer	VBN	O
for	for	IN	O
187	187	CD	O
owing	owing	NN	O
to	to	IN	O
its	-PRON-	PRP$	O
chemical	chemical	NN	O
similarity	similarity	NN	O
with	with	IN	O
71	71	CD	O
.	.	.	O

Proposed	propose	VBN	O
binding	bind	VBG	O
mode	mode	NN	O
for	for	IN	O
the	the	DT	O
active	active	JJ	O
benzoimidazole	benzoimidazole	VBD	O
71	71	CD	O
into	into	IN	O
modelled	model	VBN	O
LmjGSK-3	LmjGSK-3	NNP	O
showing	show	VBG	O
the	the	DT	O
main	main	JJ	O
interactions	interaction	NNS	O
found	find	VBN	O
in	in	IN	O
the	the	DT	O
complex	complex	NN	O
.	.	.	O

As	as	IN	O
a	a	DT	O
conclusion	conclusion	NN	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
broadened	broaden	VBN	O
the	the	DT	O
chemical	chemical	NN	O
space	space	NN	O
available	available	JJ	O
for	for	IN	O
the	the	DT	O
design	design	NN	O
of	of	IN	O
Leishmania	Leishmania	NNP	O
GSK-3	GSK-3	NNP	O
inhibitors	inhibitor	NNS	O
with	with	IN	O
leishmanicidal	leishmanicidal	JJ	O
properties	property	NNS	O
.	.	.	O

With	with	IN	O
respect	respect	NN	O
to	to	IN	O
the	the	DT	O
screening	screening	NN	O
of	of	IN	O
our	-PRON-	PRP$	O
in	in	IN	O
-	-	HYPH	O
house	house	NN	O
library	library	NN	O
of	of	IN	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
human	human	JJ	O
PKs	pk	NNS	O
,	,	,	O
we	-PRON-	PRP	O
extended	extend	VBD	O
its	-PRON-	PRP$	O
potential	potential	NN	O
from	from	IN	O
their	-PRON-	PRP$	O
former	former	JJ	O
application	application	NN	O
on	on	IN	O
human	human	JJ	O
neurodegenerative	neurodegenerative	JJ	O
syndromes	syndrome	VBZ	O
into	into	IN	O
the	the	DT	O
vast	vast	JJ	O
field	field	NN	O
of	of	IN	O
infectious	infectious	JJ	O
diseases	disease	NNS	O
.	.	.	O

Due	due	IN	O
to	to	IN	O
the	the	DT	O
importance	importance	NN	O
of	of	IN	O
these	these	DT	O
pathologies	pathology	NNS	O
in	in	IN	O
the	the	DT	O
developed	develop	VBN	O
world	world	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
huge	huge	JJ	O
effort	effort	NN	O
implemented	implement	VBN	O
by	by	IN	O
the	the	DT	O
big	big	JJ	O
pharma	pharma	NNS	O
to	to	TO	O
develop	develop	VB	O
new	new	JJ	O
PKi	PKi	NNS	O
scaffolds	scaffold	NNS	O
against	against	IN	O
them	-PRON-	PRP	O
,	,	,	O
tropical	tropical	JJ	O
diseases	disease	NNS	O
may	may	MD	O
profit	profit	VB	O
from	from	IN	O
this	this	DT	O
trend	trend	NN	O
through	through	IN	O
a	a	DT	O
drug	drug	NN	O
repurposing	repurpose	VBG	O
strategy	strategy	NN	O
,	,	,	O
as	as	IN	O
has	have	VBZ	O
happened	happen	VBN	O
with	with	IN	O
other	other	JJ	O
drugs	drug	NNS	B
.	.	.	O

With	with	IN	O
respect	respect	NN	O
to	to	IN	O
Leishbox	Leishbox	NNP	O
,	,	,	O
benzoimidazole	benzoimidazole	NN	O
,	,	,	O
N	N	NNP	O
-	-	HYPH	O
phenylpyrimidine-2-amine	phenylpyrimidine-2-amine	NNP	O
,	,	,	O
and	and	CC	O
oxadiazole	oxadiazole	RB	O
were	be	VBD	O
uncovered	uncover	VBN	O
as	as	IN	O
new	new	JJ	O
scaffolds	scaffold	NNS	O
for	for	IN	O
LdGSK-3	LdGSK-3	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
molecular	molecular	JJ	O
traits	trait	NNS	O
underlying	underlie	VBG	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
the	the	DT	O
enzyme	enzyme	NNS	O
by	by	IN	O
these	these	DT	O
compounds	compound	NNS	O
were	be	VBD	O
disclosed	disclose	VBN	O
.	.	.	O

In	in	IN	O
this	this	DT	O
regard	regard	NN	O
,	,	,	O
this	this	DT	O
work	work	NN	O
succeeded	succeed	VBD	O
in	in	IN	O
providing	provide	VBG	O
a	a	DT	O
proof	proof	NN	O
of	of	IN	O
concept	concept	NN	O
for	for	IN	O
Leishbox	Leishbox	NNP	O
as	as	IN	O
a	a	DT	O
source	source	NN	O
of	of	IN	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
Leishmania	Leishmania	NNP	O
GSK-3	GSK-3	NNP	O
.	.	.	O

Nevertheless	nevertheless	RB	O
,	,	,	O
their	-PRON-	PRP$	O
chemotherapeutical	chemotherapeutical	JJ	O
potential	potential	NN	O
will	will	MD	O
need	need	VB	O
further	further	JJ	O
validation	validation	NN	O
;	;	:	O
for	for	IN	O
instance	instance	NN	O
,	,	,	O
an	an	DT	O
endorsement	endorsement	NN	O
of	of	IN	O
their	-PRON-	PRP$	O
activities	activity	NNS	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
class	class	NN	O
of	of	IN	O
macrophages	macrophage	NNS	B
.	.	.	O

Secondly	secondly	RB	O
,	,	,	O
the	the	DT	O
poor	poor	JJ	O
inhibitory	inhibitory	JJ	O
selectivity	selectivity	NN	O
between	between	IN	O
host	host	NN	O
and	and	CC	O
parasite	parasite	VB	O
GSK-3	GSK-3	NNP	O
displayed	display	VBD	O
by	by	IN	O
the	the	DT	O
molecules	molecule	NNS	O
must	must	MD	O
be	be	VB	O
tackled	tackle	VBN	O
in	in	IN	O
future	future	JJ	O
generations	generation	NNS	O
of	of	IN	O
compounds	compound	NNS	O
.	.	.	O

Even	even	RB	O
so	so	RB	O
,	,	,	O
hGSK-3Î²	hgsk-3î²	CD	O
inhibition	inhibition	NN	O
is	be	VBZ	O
tolerated	tolerate	VBN	O
in	in	IN	O
mammalian	mammalian	JJ	O
cells	cell	NNS	O
evidence	evidence	NN	O
by	by	IN	O
the	the	DT	O
clinical	clinical	JJ	O
trials	trial	NNS	O
under	under	IN	O
current	current	JJ	O
progress	progress	NN	O
for	for	IN	O
human	human	JJ	O
pathologies	pathology	NNS	B
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
hGSK-3	hGSK-3	NNP	O
led	lead	VBD	O
to	to	IN	O
an	an	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
effect	effect	NN	O
,	,	,	O
which	which	WDT	O
may	may	MD	O
be	be	VB	O
beneficial	beneficial	JJ	O
for	for	IN	O
the	the	DT	O
excessive	excessive	JJ	O
pathological	pathological	JJ	O
inflammatory	inflammatory	JJ	O
response	response	NN	O
frequently	frequently	RB	O
associated	associate	VBN	O
with	with	IN	O
this	this	DT	O
disease	disease	NN	B
,	,	,	B
.	.	.	O

A	a	DT	O
feasible	feasible	JJ	O
solution	solution	NN	O
to	to	TO	O
increase	increase	VB	O
the	the	DT	O
specificity	specificity	NN	O
of	of	IN	O
action	action	NN	O
for	for	IN	O
these	these	DT	O
inhibitors	inhibitor	NNS	O
would	would	MD	O
be	be	VB	O
to	to	TO	O
vehicle	vehicle	VB	O
them	-PRON-	PRP	O
through	through	IN	O
the	the	DT	O
endocytic	endocytic	JJ	O
pathway	pathway	NN	O
,	,	,	O
hence	hence	RB	O
into	into	IN	O
the	the	DT	O
parasitophorous	parasitophorous	JJ	O
vacuole	vacuole	NN	O
.	.	.	O

This	this	DT	O
would	would	MD	O
promote	promote	VB	O
the	the	DT	O
preferential	preferential	JJ	O
accumulation	accumulation	NN	O
of	of	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
in	in	IN	O
the	the	DT	O
vicinity	vicinity	NN	O
of	of	IN	O
the	the	DT	O
parasite	parasite	NN	O
,	,	,	O
an	an	DT	O
approach	approach	NN	O
widely	widely	RB	O
used	use	VBN	O
for	for	IN	O
this	this	DT	O
pathology	pathology	NN	O
,	,	,	O
including	include	VBG	O
the	the	DT	O
liposomal	liposomal	JJ	O
formulation	formulation	NN	O
of	of	IN	O
amphotericin	amphotericin	NN	O
B	b	NN	O
,	,	,	O
preventing	prevent	VBG	O
the	the	DT	O
strong	strong	JJ	O
toxicity	toxicity	NN	O
of	of	IN	O
the	the	DT	O
free	free	JJ	O
drug	drug	NN	O
.	.	.	O

Work	work	VB	O
pursuing	pursue	VBG	O
these	these	DT	O
goals	goal	NNS	O
is	be	VBZ	O
currently	currently	RB	O
in	in	IN	O
progress	progress	NN	O
.	.	.	O

